<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>y72882exv2w1.htm
<DESCRIPTION>EX-2.1: AGREEMENT AND PLAN OF MERGER
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-2.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit 2.1</B>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXECUTION COPY</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AGREEMENT AND PLAN OF MERGER</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>by and among</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>JOHNSON &#038; JOHNSON,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>BINDER MERGER SUB, INC.,</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>and</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>OMRIX BIOPHARMACEUTICALS, INC.</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>November&nbsp;23, 2008</B>

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><DIV style="width: 100%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE I</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">DEFINITIONS AND TERMS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.1 Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.2 Other Definitional Provisions; Interpretation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE II</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">THE OFFER AND THE MERGER</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.1 The Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.2 Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.3 Company Actions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.4 The Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.5 Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.6 Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.7 Certificate of Incorporation and Bylaws of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.8 Directors and Officers of the Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.9 The Top-Up Option</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.10 Merger Without Meeting of Shareholders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE III</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">CONVERSION OF SHARES</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.1 Conversion of Shares </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.2 Exchange of Certificates Representing Shares </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.3 Stock Options and Other Equity-Based Awards </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.4 Dissenting Shares </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IV</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">REPRESENTATIONS AND WARRANTIES OF THE COMPANY</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.1 Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.2 Capitalization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.3 Authorization; Validity of Agreement; Company Action</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.4 Consents and Approvals; No Violations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.5 SEC Reports</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.6 No Undisclosed Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->i<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.7 Absence of Certain Changes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.8 Employee Benefit Plans; ERISA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.9 Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.10 Permits; Compliance with Law</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">33</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.11 Regulatory Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.12 Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.13 Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">39</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.14 Environmental</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.15 Labor Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.16 Offer Documents; Proxy Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.17 Takeover Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.18 Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">45</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.19 Voting Requirements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.20 Brokers or Finders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.21 Opinion of Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.22 Relationships with Customers and Suppliers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.23 No Other Representations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE V</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">REPRESENTATIONS AND WARRANTIES <br>
OF PARENT AND SUB</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.1 Organization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.2 Authorization; Validity of Agreement; Necessary Action</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.3 Consents and Approvals; No Violations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.4 Sub&#146;s Operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.5 Information Supplied</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.6 Sufficient Funds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.7 Share Ownership</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.8 Investigation by Parent and Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VI</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">COVENANTS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.1 Interim Operations of the Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.2 Advice of Changes; Filings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.3 Access to Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.4 Acquisition Proposals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">55</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.5 Employee Benefits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">57</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.6 Publicity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.7 Directors&#146; and Officers&#146; Insurance and Indemnification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.8 Company Special Meeting; Proxy Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.9 Reasonable Efforts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">61</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.10 Sub and Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.11 No Control of Other Party&#146;s Business</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->ii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.12 Israeli Tax Ruling</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">62</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.13 Certain Tax Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.14 Stockholder Litigation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.15 Rule&nbsp;14(d)-10(d) Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.16 Certain Other Actions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">CONDITIONS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.1 Conditions to Each Party&#146;s Obligation to Effect the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.2 Frustration of Conditions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE VIII</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">TERMINATION</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.1 Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.2 Effect of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">ARTICLE IX</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center"><DIV style="margin-left:15px; text-indent:-15px">MISCELLANEOUS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.1 Amendment and Modification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">67</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.2 Nonsurvival of Representations and Warranties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.3 Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.4 Interpretation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.5 Counterparts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.6 Entire Agreement; Third-Party Beneficiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.7 Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.8 Governing Law</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.9 Jurisdiction</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.10 Service of Process</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.11 Specific Performance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.12 Assignment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.13 Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.14 Headings</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.15 Waivers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">71</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Annex A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conditions to the Offer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exhibit&nbsp;A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of Tender Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exhibit&nbsp;B&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Declaration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exhibit&nbsp;C&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form of OCS Undertaking</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exhibit&nbsp;D&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1445 Tax Certificate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->iii<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGREEMENT AND PLAN OF MERGER, dated as of November&nbsp;23, 2008 (this &#147;<U>Agreement</U>&#148;), by and
among Omrix Biopharmaceuticals, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), Johnson &#038;
Johnson, a New Jersey corporation (&#147;<U>Parent</U>&#148;), and Binder Merger Sub, Inc., a Delaware
corporation and wholly owned subsidiary of Parent (&#147;<U>Sub</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, it is proposed that Sub make a cash tender offer (as it may be amended from time to
time as permitted under this Agreement, the &#147;<U>Offer</U>&#148;) to acquire all of the issued and
outstanding shares of Common Stock, par value $0.01 per share, of the Company (the
&#147;<U>Shares</U>&#148;) for $25.00 per share, net to the seller in cash (such amount, or any greater
amount per share paid pursuant to the Offer, being hereinafter referred to as the &#147;<U>Offer
Price</U>&#148;) upon the terms and subject to the conditions set forth in this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, it is proposed that, on the terms and subject to the conditions set forth in this
Agreement, following the consummation of the Offer, Sub shall merge with and into the Company (the
&#147;<U>Merger</U>&#148;), pursuant to which each Share shall be converted into the right to receive the
Offer Price, except for (i)&nbsp;Shares to be canceled pursuant to <U>Section&nbsp;3.1(c)</U> and (ii)
Dissenting Shares;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the respective Boards of Directors of the Company, Parent and Sub deem it advisable
and in the best interests of their respective stockholders that the parties consummate the
transactions contemplated by this Agreement, including the Offer and the Merger, upon the terms and
subject to the conditions set forth in this Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the respective Boards of Directors of the Company, Parent and Sub have approved this
Agreement and resolved that the transactions contemplated by this Agreement are advisable and in
the best interests of their respective stockholders, including the consummation of the Offer and
the Merger, upon the terms and subject to the conditions set forth in this Agreement and in
accordance with the relevant provisions of the General Corporation Law of the State of Delaware
(the &#147;<U>DGCL</U>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, the Board of Directors of the Company resolved to recommend that its stockholders
accept the Offer, tender their Shares in the Offer, and, to the extent required by applicable Law,
approve the Merger and adopt this Agreement and the transactions contemplated by this Agreement
(including the Offer and the Merger), in each case, upon the terms and subject to the conditions
set forth in this Agreement;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, concurrently with the execution of this Agreement, Parent, the Company and an
executive officer of the Company have entered into a tender and support agreement, dated as of the
date of this Agreement (the &#147;<U>Tender Agreement</U>&#148;), pursuant to which such executive officer
agrees to tender his Shares in the Offer, a copy of which Tender Agreement is attached as
<U>Exhibit&nbsp;A</U> to this Agreement; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the representations, warranties,
covenants and agreements set forth herein, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound
hereby, agree as follows:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt"><U><B>DEFINITIONS AND TERMS</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.1 <U>Definitions</U>. As used in this Agreement, the following terms shall have the
meanings set forth below:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acceptance Date</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acceptance Time</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acquisition Agreement</U>&#148; has the meaning set forth in <U>Section&nbsp;6.4(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Acquisition Proposal</U>&#148; means any proposal or offer made by any Person (other than
Parent, Sub or any Affiliate thereof) to purchase or otherwise acquire, directly or indirectly in
one transaction or a series of transactions, (i)&nbsp;beneficial ownership (as defined under Section
13(d) of the Exchange Act) of 15% or more of any class of equity securities of the Company pursuant
to a merger, consolidation or other business combination, sale of shares of capital stock, tender
offer or exchange offer or any other transaction involving the Company or (ii)&nbsp;any one or more
assets or businesses of the Company and its Subsidiaries that constitute 15% or more of the
revenues, net income or assets of the Company and its Subsidiaries, taken as a whole.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Affiliate</U>&#148; has the meaning set forth in Rule&nbsp;12b-2 under the Exchange Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Agreement</U>&#148; has the meaning set forth in the <U>Preamble</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Benefit Plans</U>&#148; has the meaning set forth in <U>Section&nbsp;4.8(a)</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Book-Entry Shares</U>&#148; has the meaning set forth in <U>Section&nbsp;3.1(d)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business Day</U>&#148; means a day other than a Saturday, a Sunday or another day on which
commercial banking institutions in New York, New York are authorized or required by Law to be
closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Certificate of Merger</U>&#148; has the meaning set forth in <U>Section&nbsp;2.5(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Certificates</U>&#148; has the meaning set forth in <U>Section&nbsp;3.1(d)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Change in Recommendation</U>&#148; has the meaning set forth in <U>Section&nbsp;6.4(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Cleanup</U>&#148; means all actions required to cleanup, remove, treat or remediate Hazardous
Materials in accordance with applicable Environmental Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing</U>&#148; has the meaning set forth in <U>Section&nbsp;2.6</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Date</U>&#148; has the meaning set forth in <U>Section&nbsp;2.6</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended, and applicable Treasury
Regulations issued pursuant thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company</U>&#148; has the meaning set forth in the <U>Preamble</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Disclosure Schedule</U>&#148; means the disclosure schedules delivered by the Company
to Parent simultaneously with the execution of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Intellectual Property Rights</U>&#148; has the meaning set forth in <U>Section
4.13(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Material Adverse Effect</U>&#148; means any change, effect, event, occurrence,
circumstance or development which, individually or in the aggregate, has resulted or would
reasonably be expected to result in any material adverse change in, or material adverse effect on,
the business, financial condition or results of operations of the Company and its Subsidiaries
taken as a whole; <U>provided</U>, <U>however</U>, that the effects relating or attributable to
the following shall be excluded from the determination of Company Material Adverse Effect: (w)&nbsp;any
change, effect, event, occurrence, circumstance or development in any of the industries and markets
in which the Company
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and its Subsidiaries operate or in any Laws or accounting regulations applicable to the
Company or any of its Subsidiaries (in each case to the extent they have not had, or would
reasonably be expected not to have, a disproportionate effect on the Company and its Subsidiaries
relative to other companies in the same industry as the Company); (x)&nbsp;changes in general economic
or political conditions or financial credit or securities markets in general (including changes in
interest or exchange rates) in any country or region in which the Company or its Subsidiaries
conduct business (in each case to the extent they have not had, or would reasonably be expected not
to have, a disproportionate effect on the Company and its Subsidiaries relative to other companies
in the same industry as the Company); (y)&nbsp;any acts of God, terrorism, armed hostilities, sabotage,
war or any escalation or worsening of acts of war (in each case to the extent they have not had, or
would reasonably be expected not to have, a disproportionate effect on the Company and its
Subsidiaries relative to other companies in the same industry as the Company); and (z)&nbsp;any changes
in the market price or trading volume of Shares or any failure by the Company to meet internal,
analysts&#146; or other earnings estimates or financial projections in and of themselves (for clarity,
any of the underlying causes contributing to any such changes or failures described in this clause
(z)&nbsp;shall not be excluded from the determination of Company Material Adverse Effect).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Option</U>&#148; has the meaning set forth in <U>Section&nbsp;3.3(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Permit</U>&#148; has the meaning set forth in <U>Section&nbsp;4.10</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company RSU</U>&#148; has the meaning set forth in <U>Section&nbsp;3.3(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company SEC Reports</U>&#148; has the meaning set forth in <U>Section&nbsp;4.5</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Special Meeting</U>&#148; has the meaning set forth in <U>Section&nbsp;6.8</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Company Stockholder Approval</U>&#148; means, if required by applicable Law to approve the
Merger, the affirmative vote (in person or by proxy) of the holders of a majority of the
outstanding Shares at the Company Special Meeting, or any adjournment or postponement of the
Company Special Meeting, in favor of the adoption of this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Consideration Fund</U>&#148; has the meaning set forth in <U>Section&nbsp;3.2(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Continuing Directors</U>&#148; has the meaning set forth in <U>Section&nbsp;2.2(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Dissenting Shares</U>&#148; has the meaning set forth in <U>Section&nbsp;3.4</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>DGCL</U>&#148; has the meaning set forth in the <U>Recitals</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Effective Time</U>&#148; has the meaning set forth in <U>Section&nbsp;2.5(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EMEA</U>&#148; means the European Medicines Agency.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Employees</U>&#148; has the meaning set forth in <U>Section&nbsp;6.5(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Environmental Claim</U>&#148; means any claim, notice, directive, action, cause of action,
investigation, suit, demand, abatement order or other order, lien or notice of violation by any
Person, alleging liability arising or resulting from, (a)&nbsp;the presence or Release of, or exposure
to, any Hazardous Materials or (b)&nbsp;any failure to comply with any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Environmental Laws</U>&#148; means all applicable and legally enforceable Laws relating to
pollution or protection of the environment, natural resources, the climate, endangered or
threatened species or human health and safety (as relating to exposure to Hazardous Materials),
including Laws relating to Releases of Hazardous Materials and the manufacture, processing,
distribution, use, treatment, storage, Release, transport or handling of Hazardous Materials, in
effect as of the date hereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Equity Plans</U>&#148; has the meaning set forth in <U>Section&nbsp;3.3(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ERISA</U>&#148; has the meaning set forth in <U>Section&nbsp;4.8(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ERISA Affiliate</U>&#148; has the meaning set forth in <U>Section&nbsp;4.8(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>FDCA</U>&#148; means the Federal Food, Drug and Cosmetic Act of 1938, as amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Filed SEC Reports</U>&#148; has the meaning set forth in the introductory statement to
<U>ARTICLE IV</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>GAAP</U>&#148; has the meaning set forth in <U>Section&nbsp;4.5</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Governmental Entity</U>&#148; has the meaning set forth in <U>Section&nbsp;4.4</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Grant Date</U>&#148; has the meaning set forth in <U>Section&nbsp;4.2(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Hazardous Materials</U>&#148; means (i)&nbsp;any petroleum or petroleum products, radioactive
materials or wastes, asbestos in any form, urea formaldehyde foam insulation and polychlorinated
biphenyls and (ii)&nbsp;any substance, chemical, material or waste defined as Hazardous Substances,
Oils, Pollutants or Contaminants in the National Oil and Hazardous Substances Pollution Contingency
Plan, 40 C.F.R. &#167;&nbsp;300.5, or defined as such by, or otherwise regulated or prohibited as such under,
any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Indemnified Parties</U>&#148; has the meaning set forth in <U>Section&nbsp;6.7(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Initial Expiration Time</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Insured Parties</U>&#148; has the meaning set forth in <U>Section&nbsp;6.7(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Intellectual Property Rights</U>&#148; means all (i)&nbsp;patents and applications therefor, (ii)
trademarks, service marks, brand names, logos, slogans, trade dress and applications and
registrations therefor (&#147;<U>Trademarks</U>&#148;), (iii)&nbsp;domain name registrations, (iv)&nbsp;copyright,
copyright registrations and applications therefor and all other rights corresponding thereto, (v)
trade name rights, (vi)&nbsp;trade secret or know-how rights, (vii)&nbsp;rights in computer programs or
software or (viii)&nbsp;other types of intellectual property rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>IRS</U>&#148; means the United States Internal Revenue Service.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Israeli Anti-Trust Law</U>&#148; means the Restrictive Trade Practices Law 5748&#150; 1988 and the
regulations promulgated thereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Israeli Employees</U>&#148; has the meaning set forth in <U>Section&nbsp;6.5(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Israeli Equity Plan</U>&#148; means the 2005 Equity Incentive Plan for Israeli Employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Israeli Tax Ruling</U>&#148; has the meaning set forth in <U>Section&nbsp;6.12</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ITA</U>&#148; means the Israeli Tax Authorities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>knowledge</U>&#148; means such facts and other information that as of the date of
determination are actually known to the persons identified on <U>Section&nbsp;1.1</U> of the Company
Disclosure Schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Law</U>&#148; means any federal, state, local or foreign law, statute, ordinance, rule,
regulation, judgment, order, decree, injunction, arbitration award, franchise, license, agency
requirement or permit of any Governmental Entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Merger</U>&#148; has the meaning set forth in <U>Section&nbsp;2.4</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Merger Consideration</U>&#148; has the meaning set forth in <U>Section&nbsp;3.1(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Minimum Condition</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Nondisclosure Agreement</U>&#148; has the meaning set forth in <U>Section&nbsp;2.3(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Notice of Adverse Recommendation</U>&#148; has the meaning set forth in <U>Section
6.4(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Notice of Superior Proposal</U>&#148; has the meaning set forth in <U>Section&nbsp;6.4(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>OCS</U>&#148; has the meaning set forth in <U>Section&nbsp;4.4</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Offer</U>&#148; has the meaning set forth in the <U>Recitals</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Offer Documents</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(d)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Offer Price</U>&#148; has the meaning set forth in the <U>Recitals</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Option Consideration</U>&#148; has the meaning set forth in <U>Section&nbsp;3.3(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent</U>&#148; has the meaning set forth in the <U>Preamble</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Company</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Material Adverse Effect</U>&#148; means any change, effect, event, occurrence,
circumstance or development which, individually or in the aggregate, would reasonably be expected
to prevent or materially impede, interfere with, hinder or delay the consummation by Parent or Sub
of the transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Parent Plans</U>&#148; has the meaning set forth in <U>Section&nbsp;6.5(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Participant</U>&#148; means any current or former director, officer, employee or consultant of
the Company or any of its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Paying Agent</U>&#148; has the meaning set forth in <U>Section&nbsp;3.2(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Person</U>&#148; means an individual, corporation, limited liability company, partnership,
association, trust, unincorporated organization, other entity or group (as defined in the Exchange
Act).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Proxy Statement</U>&#148; has the meaning set forth in <U>Section&nbsp;6.8</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Regulatory Authority</U>&#148; means the FDA, the EMEA and any other federal, state, local or
foreign Governmental Entity that is concerned with the marketing, sale, use handling and control,
safety, efficacy, reliability, or manufacturing of drug or biological products or medical devices.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Release</U>&#148; means any actual or threatened release, spill, emission, discharge, leaking,
pumping, dumping, injection, deposit, disposal, dispersal, leaching or migration, including the
movement through or in the air, soil, surface water or groundwater or any real property, building
or fixture.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Representatives</U>&#148; has the meaning set forth in <U>Section&nbsp;6.3</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Restricted Stock Award</U>&#148; has the meaning set forth in <U>Section&nbsp;3.3(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Schedule&nbsp;14D-9</U>&#148; has the meaning set forth in <U>Section&nbsp;2.3(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>SEC</U>&#148; means the United States Securities and Exchange Commission.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Shares</U>&#148; has the meaning set forth in the <U>Recitals</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Short Form&nbsp;Merger</U>&#148; has the meaning set forth in <U>Section&nbsp;2.10</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Specified Benefit Agreements</U>&#148; has the meaning set forth in <U>Section&nbsp;4.7</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Specified Contracts</U>&#148; has the meaning set forth in <U>Section&nbsp;4.18(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Specified Participant</U>&#148; means any current or former director or officer of the Company
or any of its Subsidiaries, or any other employee of the Company or any of its Subsidiaries who
reports directly to the Company&#146;s President and Chief Operating Officer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Sub</U>&#148; has the meaning set forth in the <U>Preamble</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Subsequent Offering Period</U>&#148; has the meaning set forth in <U>Section&nbsp;2.1(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Subsidiary</U>&#148; means, as to any Person, any Person (i)&nbsp;of which such first Person
directly or indirectly owns securities or other equity interests representing more than fifty
percent (50%) of the aggregate voting power, or (ii)&nbsp;of which such first Person possesses the right
to elect more than fifty percent (50%) of the directors or Persons holding similar positions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Superior Proposal</U>&#148; means any <U>bona</U> <U>fide</U> offer made by any Person
(other than Parent, Sub or any Affiliate thereof) that if accepted would result in such person (or
its stockholders) owning, directly or indirectly, all or substantially all the Shares then
outstanding (or of the surviving entity in a merger or the direct or indirect parent of the
surviving entity in a merger) or all or substantially all the assets of the Company, which the
Company&#146;s Board of Directors determines in good faith, after consultation with the Company&#146;s
outside legal counsel and financial advisor, to be (i)&nbsp;more favorable from a financial point of
view to the Company&#146;s stockholders than the transactions contemplated hereby&nbsp;(taking into account
all the terms and conditions of such offer and this Agreement (including any changes to the terms
of this Agreement proposed by Parent in response to such offer or otherwise)) and (ii)&nbsp;reasonably
capable of being completed, taking into account all financial, legal, regulatory and other aspects
of such offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Surviving Corporation</U>&#148; has the meaning set forth in <U>Section&nbsp;2.4</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Tax Return</U>&#148; means any report, return, document, declaration or other information or
filing required to be filed, including requests for extensions of time, filings made with estimated
tax payments, claims for refund and amended returns that may be filed with any taxing authority or
jurisdiction (foreign or domestic) with respect to Taxes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Taxes</U>&#148; means any and all taxes, charges, fees, levies or other assessments, including
income, gross receipts, margin, capital, assets, alternative, excise, real or personal property,
sales, use, withholding, social security, occupation, service, service use, value added, license,
net worth, payroll, franchise, transfer and recording taxes, fees and charges, imposed by the IRS
or any taxing authority (whether domestic or foreign including any state, local or foreign
government or any subdivision or taxing agency thereof (including a United States possession)),
whether computed on a separate, consolidated, unitary, combined or any other basis or as a
transferee or successor or by contract, indemnity or otherwise; and such term shall include any
interest, penalties or additional amounts attributable to, or imposed upon, or with respect to, any
such taxes, charges, fees, levies or other assessments.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Termination Date&#148; has the meaning set forth in Section&nbsp;8.1(b)(i)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Top-Up Closing&#148; has the meaning set forth in Section&nbsp;2.9(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Top-Up Option&#148; has the meaning set forth in Section&nbsp;2.9(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Top-Up Shares&#148; has the meaning set forth in Section&nbsp;2.9(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Trustee&#148; has the meaning set forth in Section&nbsp;3.3(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>US Employees&#148; has the meaning set forth in Section&nbsp;6.5(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Warrants&#148; has the meaning set forth in Section&nbsp;4.2(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.2 <U>Other Definitional Provisions; Interpretation</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The words &#147;hereof,&#148; &#147;herein&#148; and &#147;herewith&#148; and words of similar import shall, unless
otherwise stated, be construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement, and references to articles, sections, paragraphs, exhibits, annexes
and schedules are to the articles, sections and paragraphs of, and exhibits, annexes and schedules
to, this Agreement, unless otherwise specified.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Whenever the words &#147;include,&#148; &#147;includes&#148; or &#147;including&#148; are used in this Agreement, they
shall be deemed to be followed by the phrase &#147;without limitation.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Words describing the singular number shall be deemed to include the plural and vice versa,
words denoting any gender shall be deemed to include all genders and words denoting natural persons
shall be deemed to include business entities and vice versa.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;When used in reference to information or documents, the phrase &#147;made available&#148; means that
the information or documents referred to have been made available to the party to which such
information or documents are to be made available.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The phrases &#147;the date of this Agreement&#148; and &#147;the date hereof&#148; and terms or phrases of
similar import shall be deemed to refer to November&nbsp;23, 2008, unless the context requires
otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The term &#147;material&#148; shall be measured against the Company and its Subsidiaries as a whole.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;References to any statute are to that statute, as amended from time to time, and to the
rules and regulations promulgated thereunder, in effect as of the date of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Terms defined in the text of this Agreement have such meaning throughout this Agreement,
unless otherwise indicated in this Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>THE OFFER AND THE MERGER</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.1 <U>The Offer</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Provided that this Agreement shall not have been terminated in accordance with <U>Section
8.1</U>, Sub shall commence (within the meaning of Rule&nbsp;14d-2(a) of the Exchange Act) the Offer as
promptly as practicable after the date hereof (but not later than the fifth (5th) Business Day from
and including the date of initial public announcement of this Agreement). The obligation of Sub to
commence the Offer shall be subject only to the condition that none of the events set forth in
clauses (v)(a) or (v)(b) of <U>Annex A</U> hereto shall have occurred and be continuing (and not
waived by Parent or Sub
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">in their sole discretion), and the obligation of Sub to accept for payment, purchase and pay
for Shares tendered pursuant to the Offer shall be subject only to the satisfaction (or waiver by
Parent or Sub in their sole discretion (but subject to the next sentence)) of the conditions set
forth in such <U>Annex A</U>. Sub expressly reserves the right to waive any conditions to the
Offer or change the terms of the Offer except that, without the prior written consent of the
Company, Sub may not waive the condition in clause (i)&nbsp;of <U>Annex A</U> (the &#147;<U>Minimum
Condition</U>&#148;) or the condition in clause (ii)&nbsp;or (iii)&nbsp;of <U>Annex A</U>, and no change in the
Offer may be made which (i)&nbsp;decreases the Offer Price payable in the Offer, (ii)&nbsp;changes the form
of consideration to be paid in the Offer, (iii)&nbsp;reduces the maximum number of Shares to be
purchased in the Offer or the minimum number of Shares contemplated by the Minimum Condition, (iv)
imposes conditions to the Offer in addition to those set forth in <U>Annex A</U> hereto or which
otherwise modifies the conditions set forth in such <U>Annex A</U> or (v)&nbsp;amends any other term of
the Offer in a manner adverse to the holders of Shares. Subject to the terms and conditions of the
Offer and this Agreement, Sub shall, and Parent shall cause Sub to, accept for payment, purchase
and pay for all Shares validly tendered and not withdrawn pursuant to the Offer as soon as
practicable after the expiration of the Offer (the date of acceptance for payment, the
&#147;<U>Acceptance Date</U>&#148; and the time of acceptance for payment on the Acceptance Date, the
&#147;<U>Acceptance Time</U>&#148;) or (in the case of Shares tendered during any Subsequent Offering
Period) as soon as practicable following the valid tender thereof without interest, subject to any
withholding of Taxes required by applicable Law or in accordance with Sections&nbsp;3.2(i) and (j).
Parent shall provide or cause to be provided to Sub on a timely basis funds sufficient to purchase
and pay for any and all Shares that Sub becomes obligated to accept for payment, purchase and pay
for pursuant to the Offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Unless extended as provided in this Agreement, the Offer shall expire on the date (the
&#147;<U>Initial Expiration Time</U>&#148;) that is twenty (20)&nbsp;Business Days after the commencement of the
Offer (determined pursuant to Rule&nbsp;14d-1(g)(3) under the Exchange Act). Sub may, without the
consent of the Company, (i)&nbsp;extend the Offer on one or more occasions for any period not exceeding
ten (10)&nbsp;Business Days for any extension, if on any then-scheduled expiration date of the Offer any
of the events set forth in <U>Annex A</U> shall have occurred and be continuing, until such time
as such event or events shall no longer exist, and (ii)&nbsp;extend the Offer for any period required by
any rule, regulation, interpretation or position of the SEC or the staff thereof applicable to the
Offer. If, at the Initial Expiration Time or subsequent expiration time related to an extension of
the Offer, including an extension pursuant to this sentence, any of the conditions to the
obligation of Sub to accept for payment, purchase and pay for Shares tendered pursuant to the Offer
has not been satisfied (or waived in accordance with this Agreement), then, if requested by the
Company, Sub shall, and Parent shall cause Sub to, extend the Offer through such time as the
Company may specify, which time shall be no later than the Termination Date; <U>provided</U> that
the Company shall not be entitled to so request such an extension if any of the conditions set
forth in clause (v)(b) or (v)(c) of <U>Annex A</U> have not then been satisfied or waived in
accordance with this Agreement (other than any such conditions that are not so satisfied or waived
under circumstances in which the breach or breaches preventing such conditions from being satisfied
may, by their nature, be cured by the Company through the exercise of its reasonable efforts for a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">period not greater than thirty (30)&nbsp;days, in which case the Company may (if all other
conditions set forth in clause (v)(b) or (v)(c) of <U>Annex A</U> are satisfied) request one or
more extensions of the Offer pursuant to this sentence for up to thirty (30)&nbsp;days in the
aggregate). Nothing in this <U>Section&nbsp;2.1(b)</U> shall affect or impair any termination rights
under <U>ARTICLE VIII</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;If all of the conditions to the Offer are satisfied or waived, but the number of Shares
validly tendered and not withdrawn, together with the Shares, if any, held by Parent and Sub or any
other direct or indirect wholly owned Subsidiary of Parent (any such wholly owned Subsidiaries of
Parent, Parent and Sub, each a &#147;<U>Parent Company</U>&#148;), constitute less than the number of Shares
required to consummate the Merger pursuant to <U>Section&nbsp;2.10</U> (assuming the exercise of the
Top-Up Option in full), then, upon the applicable expiration time of the Offer, Sub may (and if the
Company so requests Sub shall, and Parent shall cause Sub to) provide a subsequent offering period
(a &#147;<U>Subsequent Offering Period</U>&#148;) in accordance with Rule&nbsp;14d-11 under the Exchange Act and,
if applicable and to the extent permitted under such Rule&nbsp;14d-11, thereafter extend such subsequent
offering period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;As soon as practicable on the date the Offer is commenced, Parent and Sub shall file with
the SEC a Tender Offer Statement on Schedule&nbsp;TO with respect to the Offer, which shall include the
offer to purchase, form of the related letter of transmittal and form of notice of guaranteed
delivery and all other ancillary Offer documents (collectively, together with any amendments and
supplements thereto, the &#147;<U>Offer Documents</U>&#148;). The Offer Documents will comply in all
material respects with the applicable provisions of the Exchange Act. Parent and Sub shall cause
the Offer Documents to be disseminated to holders of Shares as required by applicable federal
securities Laws. Parent and Sub, on the one hand, and the Company, on the other hand, agree to
promptly correct any information provided by it for use in the Offer Documents if it shall have
become false or misleading in any material respect or as otherwise required by applicable Law. Sub
further agrees to take all steps necessary to cause the Offer Documents as so corrected to be filed
with the SEC and disseminated to holders of Shares as required by applicable federal securities
Laws. The Company and its counsel shall be given a reasonable opportunity to review and comment on
the Offer Documents before they are filed with the SEC or disseminated to holders of Shares, and
Parent and Sub shall give due consideration to all reasonable additions, deletions or changes
suggested thereto by the Company and its counsel. In addition, Parent and Sub agree to provide the
Company and its counsel any comments or communications, whether written or oral, that Parent, Sub
or their counsel may receive from time to time from the SEC or its staff with respect to the Offer
Documents promptly after Parent&#146;s or Sub&#146;s, as the case may be, receipt of such comments or
communications. The Company and its counsel shall be given a reasonable opportunity to review any
responses to such comments or communications, and Parent and Sub shall give due consideration to
all reasonable additions, deletions or changes suggested thereto by the Company and its counsel.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.2 <U>Directors</U>.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Subject to compliance with applicable Law, promptly upon the payment by Sub for Shares
pursuant to the Offer representing at least such number of Shares as shall satisfy the Minimum
Condition, and from time to time thereafter, Parent shall be entitled to designate such number of
directors, rounded up to the next whole number, on the Company&#146;s Board of Directors as is equal to
the product of the total number of directors on the Company&#146;s Board of Directors (determined after
giving effect to the directors elected pursuant to this sentence) multiplied by the percentage that
the aggregate number of Shares beneficially owned by Parent, Sub or their Affiliates at such time
(including Shares so accepted for payment and any Top-Up Shares) bears to the total number of
Shares then outstanding; <U>provided</U>, <U>however</U>, that Parent shall be entitled to
designate at least a majority of the directors on the Company&#146;s Board of Directors (as long as
Parent and its Affiliates beneficially own a majority of the Shares of the Company). In
furtherance thereof, the Company shall, upon request of Parent and subject to the terms of the
Company&#146;s certificate of incorporation and by-laws, promptly take all actions necessary to cause
Parent&#146;s designees to be so elected or appointed, including, without limitation, increasing the
size of its Board of Directors and/or seeking the resignations of one or more incumbent directors.
At such times, subject to <U>Section&nbsp;2.2(c)</U> and applicable Law and regulations and the rules
of Nasdaq Global Market, Inc., the Company will cause individuals designated by Parent to
constitute such number of members of each committee of the Company&#146;s Board of Directors, rounded up
to the next whole number, that represents the same percentage as such individuals represent on the
Company&#146;s Board of Directors, other than any committee of the Company&#146;s Board of Directors
established to take action under this Agreement which committee shall be composed only of
Continuing Directors (as defined in <U>Section&nbsp;2.2(c)</U>).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Company&#146;s obligations to appoint Parent&#146;s designees to the Company&#146;s Board of
Directors shall be subject to Section 14(f) of the Exchange Act and Rule&nbsp;14f-l thereunder. The
Company shall promptly take all actions required pursuant to Section 14(f) and Rule&nbsp;14f-1 in order
to fulfill its obligations under this <U>Section&nbsp;2.2</U>, including mailing to stockholders
together with the Schedule&nbsp;14D-9 the information required under Section 14(f) and Rule&nbsp;14f-1 as is
necessary to enable Parent&#146;s designees to be elected to the Company&#146;s Board of Directors. Parent
shall supply to the Company, and shall be solely responsible for, any information with respect to
itself and its officers, directors and Affiliates to the extent required by Section 14(f) and Rule
14f-1. The provisions of this <U>Section&nbsp;2.2</U> are in addition to and shall not limit any
rights that Parent, Sub or any of their Affiliates may have as a holder or beneficial owner of
Shares as a matter of applicable Law with respect to the election of directors or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;In the event that Parent&#146;s designees are elected or appointed to the Company&#146;s Board of
Directors pursuant to this <U>Section&nbsp;2.2</U> then, until the Effective Time, the Company shall
cause the Company&#146;s Board of Directors to maintain at least three directors who are members of the
Company&#146;s Board of Directors on the date of this Agreement and who are not officers of the Company
and who are independent directors for purposes of the continued listing requirements of Nasdaq
Global Market, Inc. (the &#147;<U>Continuing Directors</U>&#148;); <U>provided</U>, <U>however</U>, that
if the number of Continuing Directors
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">is reduced below three for any reason, the remaining Continuing Directors shall be entitled to
elect or designate a person to fill such vacancy who shall be deemed to be a Continuing Director
for purposes of this Agreement or, if no Continuing Directors then remain, the other directors
shall designate three persons to fill such vacancies who are not officers, employees, stockholders
or Affiliates of the Company, Parent or Sub, and such persons shall be deemed to be Continuing
Directors for purposes of this Agreement. The Company and the Company&#146;s Board of Directors shall
promptly take all action as may be necessary to comply with their obligations under this
<U>Section&nbsp;2.2(c)</U>. Notwithstanding anything in this Agreement to the contrary, following the
time directors designated by Parent are elected or appointed to the Company&#146;s Board of Directors
and prior to the Effective Time, the Company&#146;s Board of Directors shall take such action as
necessary so that the affirmative vote of a majority of the Continuing Directors (or of the sole
Continuing Director if there shall then be only one Continuing Director) shall be required, and no
further action of the Company&#146;s Board of Directors shall be required, to (v)&nbsp;amend or terminate
this Agreement on behalf of the Company, (w)&nbsp;exercise or waive any of the Company&#146;s rights or
remedies hereunder, (x)&nbsp;extend the time for performance of Parent&#146;s or Sub&#146;s obligations hereunder,
(y)&nbsp;take any action adversely affecting the rights of the Company&#146;s stockholders, or (z)&nbsp;take any
other action by the Company in connection with this Agreement and the transactions contemplated
hereby. The Continuing Directors shall have the authority to retain counsel and financial advisors
of their choice at the reasonable expense of the Company as determined appropriate by the
Continuing Directors for the purpose of fulfilling their obligations hereunder and shall have the
authority, after the Acceptance Time, to institute any action on behalf of the Company to enforce
the performance of this Agreement in accordance with its terms; <U>provided</U>, <U>however</U>,
that Parent shall have received at least two Business Days&#146; prior notice of the proposed
commencement of any such action. Following the acceptance for payment of the Shares pursuant to
the Offer and prior to the Effective Time, neither Parent nor Sub shall take any action to remove
any Continuing Director absent cause and subject to the terms of the Company&#146;s certificate of
incorporation and bylaws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.3 <U>Company Actions</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;On the date the Offer Documents are filed with the SEC, the Company shall file with the
SEC a Tender Offer Solicitation/Recommendation Statement on Schedule&nbsp;14D-9 (together with all
amendments, supplements and exhibits thereto, the &#147;<U>Schedule&nbsp;14D-9</U>&#148;) which shall, subject to
the provisions of <U>Section&nbsp;6.4(c)</U>, contain the recommendation that the holders of the Shares
accept the Offer, tender their Shares to Sub pursuant to the Offer and, if a vote of the
stockholders of the Company is required to consummate the Merger under the DGCL, adopt this
Agreement. The Schedule&nbsp;14D-9 will comply in all material respects with the applicable provisions
of the Exchange Act. The Company agrees to cause the Schedule&nbsp;14D-9 to be disseminated to holders
of Shares as required by applicable federal securities Laws. The Company, on the one hand, and
Parent and Sub, on the other hand, agree to promptly correct any information provided by it for use
in the Schedule&nbsp;14D-9 if it shall have become false or misleading in any material respect or as
otherwise required by applicable Law. The Company agrees to take all reasonable steps necessary to
cause the Schedule&nbsp;14D-9 as so corrected to be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">filed with the SEC and disseminated to holders of Shares as required by applicable federal
securities Laws. Parent, Sub and their counsel shall be given a reasonable opportunity to review
and comment on the Schedule&nbsp;14D-9 before it is filed with the SEC or disseminated to holders of
Shares, and the Company shall give due consideration to all reasonable additions, deletions or
changes suggested thereto by Parent, Sub and their counsel. In addition, the Company agrees to
provide Parent, Sub and their counsel with any comments or communications that the Company or its
counsel may receive from time to time from the SEC or its staff with respect to the Schedule&nbsp;14D-9
promptly after the Company&#146;s receipt of such comments or communications. Parent, Sub and their
counsel shall be given a reasonable opportunity to review any responses to such comments or
communications, and the Company shall give due consideration to all reasonable additions, deletions
or changes suggested thereto by Parent, Sub and their counsel.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;In connection with the Offer, the Company shall, or shall cause its transfer agent to,
promptly furnish to Sub mailing labels, security position listings and any available listing or
computer file containing the names and addresses of the record holders of Shares as of a recent
date, and shall furnish Sub with such information and assistance (including, but not limited to,
lists of holders of the Shares, updated periodically, and their addresses, mailing labels and lists
of security positions) as Sub may reasonably request in communicating the Offer to holders of
Shares. The nondisclosure agreement, dated August&nbsp;1, 2008 (as amended or supplemented, the
&#147;<U>Nondisclosure Agreement</U>&#148;), between the Company and Parent shall apply with respect to
information furnished to Sub in accordance with this <U>Section&nbsp;2.3(b)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.4 <U>The Merger</U>. Subject to the terms and conditions of this Agreement and in
accordance with the DGCL, at the Effective Time, the Company and Sub shall consummate a merger (the
&#147;<U>Merger</U>&#148;) pursuant to which (i)&nbsp;Sub shall merge with and into the Company and the separate
corporate existence of Sub shall thereupon cease and (ii)&nbsp;the Company shall be the surviving
corporation (the &#147;<U>Surviving Corporation</U>&#148;) in the Merger and shall continue to be governed
by the laws of the State of Delaware. The Merger shall have the effects set forth in the DGCL.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.5 <U>Effective Time</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Parent, Sub and the Company shall cause a certificate of merger (the &#147;<U>Certificate of
Merger</U>&#148;) to be filed on the Closing Date (or on such other date as Parent and the Company may
agree in writing) with the Secretary of State of the State of Delaware as provided in the DGCL, and
shall make all other filings or recordings required by the DGCL in connection with the Merger. The
Merger shall become effective at the time at which the Certificate of Merger is duly filed with the
Secretary of State of the State of Delaware or at such later time as is agreed upon in writing by
the parties and specified in the Certificate of Merger, and such time is hereinafter referred to as
the &#147;<U>Effective Time</U>.&#148;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;From and after the Effective Time, the Surviving Corporation shall possess all properties,
rights, privileges, powers and franchises of the Company and Sub, and all of the claims,
obligations, liabilities, debts and duties of the Company and Sub shall become the claims,
obligations, liabilities, debts and duties of the Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.6 <U>Closing</U>. The closing of the Merger (the &#147;<U>Closing</U>&#148;) will take place at
9:00 a.m., New York time, on a date to be specified by the parties, which shall be no later than
two (2)&nbsp;Business Days after the satisfaction or waiver of all of the conditions set forth in
<U>ARTICLE VII</U> hereof (other than conditions that by their terms are to be satisfied at the
Closing, but subject to the satisfaction or waiver of such conditions at the Closing), at the
offices of Skadden, Arps, Slate, Meagher &#038; Flom LLP, Four Times Square, New York, New York, unless
another time, date or place is agreed to in writing by the parties hereto; <U>provided</U>,
<U>however</U>, that if, as of or immediately following the Acceptance Date or the expiration of
any Subsequent Offering Period pursuant to <U>Section&nbsp;2.1(c)</U>, a Short Form&nbsp;Merger is available
pursuant to <U>Section&nbsp;2.10</U> and Section&nbsp;253 of the DGCL, the Closing shall, subject to the
satisfaction or waiver of the conditions set forth in <U>ARTICLE VII</U>, occur as soon as is
practicable following the Acceptance Date or the expiration of such Subsequent Offering Period, as
applicable. The date on which the Closing is to take place is referred to in this Agreement as the
&#147;<U>Closing Date</U>&#148;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.7 <U>Certificate of Incorporation and Bylaws of the Surviving Corporation</U>. The
certificate of incorporation and bylaws of Sub, as in effect immediately prior to the Effective
Time, shall be the certificate of incorporation and bylaws of the Surviving Corporation, except as
to the name of the Surviving Corporation, which shall be Omrix Biopharmaceuticals, Inc., until
thereafter amended as provided by Law, and by such certificate of incorporation and bylaws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.8 <U>Directors and Officers of the Surviving Corporation</U>. The directors of Sub
immediately prior to the Effective Time shall, from and after the Effective Time, be the initial
directors of the Surviving Corporation until their successors shall have been duly elected or
appointed or qualified or until their earlier death, resignation or removal in accordance with the
Surviving Corporation&#146;s certificate of incorporation and bylaws. The officers of Sub immediately
prior to the Effective Time shall, from and after the Effective Time, be the initial officers of
the Surviving Corporation until their successors shall have been duly elected or appointed or
qualified or until their earlier death, resignation or removal in accordance with the Surviving
Corporation&#146;s certificate of incorporation and bylaws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.9 <U>The Top-Up Option</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company hereby grants to Sub an irrevocable option (the &#147;<U>Top-Up Option&#148;</U>) to
purchase that number of Shares (the &#147;<U>Top-Up Shares</U>&#148;) equal to the lowest number of Shares
that, when added to the number of Shares owned by Parent, Sub or their Affiliates at the time of
such exercise, shall constitute one share more than ninety percent (90%) of the total Shares then
outstanding on a fully-diluted basis
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(assuming the issuance of the Top-Up Shares), at a price per share equal to the Offer Price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Top-Up Option shall be exercisable once, in whole and not in part, on or after the
Acceptance Time (so long as the exercise of the Top-Up Option would, after issuance of such Shares,
be sufficient to allow the Short Form&nbsp;Merger to occur; <U>provided</U>, <U>however</U>, that in
no event shall the Top-Up Option be exercisable for a number of Shares in excess of (x)&nbsp;the number
of authorized but unissued Shares (including as authorized and unissued Shares, for purposes of
this <U>Section&nbsp;2.9</U>, any Shares held in the treasury of the Company) or (y)&nbsp;19.90% of the
number of outstanding Shares or voting power of the Company, in each case as of immediately prior
to and after giving effect to the issuance of the Top-Up Shares; and <U>provided further</U>, that
the Top-Up Option shall terminate upon the earlier of: (i)&nbsp;the fifth (5th) business day after the
later of (1)&nbsp;the Acceptance Time and (2)&nbsp;the expiration of any Subsequent Offering Period; and (ii)
the termination of this Agreement in accordance with its terms. The obligation of the Company to
deliver Top-Up Shares upon the exercise of the Top-Up Option is subject to the conditions that (A)
no provision of any applicable Law and no judgment, injunction, order or decree shall prohibit the
exercise of the Top-Up Option or the delivery of the Top-Up Shares in respect of such exercise, (B)
upon exercise of the Top-Up Option, the number of Shares owned by Parent, Sub and their Affiliates
constitutes one Share more than ninety percent (90%) of the number of Shares that will be
outstanding on a fully-diluted basis immediately after the issuance of the Top-Up Shares,
and (C)&nbsp;Sub has accepted for payment all Shares validly tendered in the Offer and not withdrawn.
The parties shall cooperate to ensure that the issuance of the Top-Up Shares is accomplished
consistent with all applicable legal requirements of all Governmental Entities, including
compliance with an applicable exemption from registration of the Top-Up Shares under the Securities
Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;To exercise the Top-Up Option, Sub shall so notify the Company in writing, and shall set
forth in such notice (i)&nbsp;the number of Shares that will be owned by Parent, Sub and their
Affiliates immediately preceding the purchase of the Top-Up Shares and (ii)&nbsp;the place and time for
the closing of the purchase of the Top-Up Shares (the &#147;<U>Top-Up Closing</U>&#148;). The Company
shall, as soon as practicable following receipt of such notice, notify Parent and Sub in writing of
the number of Shares then outstanding and the number of Top-Up Shares. At the Top-Up Closing, Sub
shall pay the Company in cash by wire transfer the aggregate price required to be paid for the
Top-Up Shares and the Company shall cause to be issued to Sub a certificate representing the Top-Up
Shares, which certificate may include any legends required by applicable securities Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Parent and Sub acknowledge that the Shares which Sub may acquire upon exercise of the
Top-Up Option will not be registered under the Securities Act and will be issued in reliance upon
an exemption for transactions not involving a public offering. Parent and Sub represent and
warrant to the Company that Sub is, or will
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">be upon any purchase of Top-Up Shares, an &#147;accredited investor&#148;, as defined in Rule&nbsp;501 of
Regulation&nbsp;D under the Securities Act. Sub agrees that the Top-Up Option, and the Top-Up Shares to
be acquired upon exercise of the Top-Up Option, if any, are being and will be acquired by Sub for
the purpose of investment and not with a view to, or for resale in connection with, any
distribution thereof (within the meaning of the Securities Act).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.10 <U>Merger Without Meeting of Shareholders</U>. Notwithstanding anything to the
contrary in <U>Section&nbsp;6.8</U>, in the event that any Parent Company, whether pursuant to the
Offer, upon exercise of the Top-Up Option or otherwise, shall acquire at least ninety percent (90%)
of the outstanding Shares, the parties hereto agree, subject to <U>ARTICLE VII</U>, to take all
necessary and appropriate actions to cause the Merger to become effective as soon as practicable
after such acquisition, without a meeting of shareholders of the Company, in accordance with
Section&nbsp;253 of the DGCL (a &#147;<U>Short Form&nbsp;Merger</U>&#148;). Notwithstanding anything to the contrary
in this Agreement, if the conditions set forth in <U>Section&nbsp;2.9(b)</U> have been satisfied, Sub
shall exercise the Top-Up Option as promptly as practicable following the Acceptance Time.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>CONVERSION OF SHARES</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.1 <U>Conversion of Shares</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;At the Effective Time, each Share issued and outstanding immediately prior to the
Effective Time (other than Shares to be cancelled pursuant to <U>Section&nbsp;3.1(c)</U> and Dissenting
Shares) shall, by virtue of the Merger and without any action on the part of the holder thereof, be
converted into the right to receive the Offer Price in cash (the &#147;<U>Merger Consideration</U>&#148;),
without any interest thereon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each share of common stock, par value $0.01 per share, of Sub issued and outstanding
immediately prior to the Effective Time shall, at the Effective Time, by virtue of the Merger and
without any action on the part of Parent, be converted into one fully paid and nonassessable share
of the common stock, par value $0.01 per share, of the Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Share held by the Company as treasury stock or owned by Parent or Sub immediately
prior to the Effective Time shall, at the Effective Time, be cancelled and retired and shall cease
to exist, and no consideration shall be delivered in exchange therefor.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Except as set forth in <U>Section&nbsp;3.3(c)</U>, at the Effective Time, each Share converted
into the right to receive the Merger Consideration without any interest thereon pursuant to
<U>Section&nbsp;3.1(a)</U> shall be automatically cancelled and shall cease to exist, and the holders
immediately prior to the Effective Time of outstanding Shares not represented by certificates
(&#147;<U>Book-Entry Shares</U>&#148;) and the holders of certificates that, immediately prior to the
Effective Time, represented outstanding Shares (the &#147;<U>Certificates</U>&#148;) shall cease to have any
rights with respect to such Shares other than the right to receive, upon surrender of such
Book-Entry Shares or Certificates in accordance with <U>Section&nbsp;3.2</U>, the Merger Consideration,
without any interest thereon, for each such Share held by them.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.2 <U>Exchange of Certificates Representing Shares</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;At or prior to the Closing, Parent shall deliver or cause to be delivered, in trust, to a
bank or trust company designated by Parent and reasonably satisfactory to the Company (the
&#147;<U>Paying Agent</U>&#148;), for the benefit of the holders of Shares immediately prior to the
Effective Time (other than holders of Shares to be cancelled pursuant to <U>Section&nbsp;3.1(c)</U> and
Dissenting Shares), sufficient funds for timely payment of the aggregate Merger Consideration (such
cash being hereinafter referred to as the &#147;<U>Consideration Fund</U>&#148;) to be paid pursuant to this
<U>Section&nbsp;3.2</U> in exchange for all outstanding Shares immediately prior to the Effective Time
(other than Shares to be cancelled pursuant to <U>Section&nbsp;3.1(c)</U> and Dissenting Shares). The
Consideration Fund shall not be used for any other purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Promptly after the Effective Time, Parent shall cause the Paying Agent to mail to each
holder of record of Certificates or Book-Entry Shares whose Shares were converted into the right to
receive Merger Consideration pursuant to <U>Section&nbsp;3.1(a)</U>, (i)&nbsp;a letter of transmittal that
shall specify that delivery of such Certificates or Book-Entry Shares shall be deemed to have
occurred, and risk of loss and title to the Certificates or Book-Entry Shares, as applicable, shall
pass, only upon proper delivery of the Certificates (or affidavits of loss in lieu thereof together
with any required indemnity) or Book-Entry Shares to the Paying Agent and (ii)&nbsp;instructions for use
in effecting the surrender of the Certificates or Book-Entry Shares in exchange for payment of the
Merger Consideration, the form and substance of which letter of transmittal and instructions shall
be substantially as reasonably agreed to by the Company and Parent and prepared prior to the
Closing. Upon surrender of a Book-Entry Share or a Certificate for cancellation to the Paying
Agent together with such letter of transmittal, duly executed and completed in accordance with the
instructions thereof, and with such other documents as may be required pursuant to such
instructions, the holder of such Book-Entry Share or Certificate shall be entitled to receive in
exchange therefor, subject to any required withholding of Taxes, the Merger Consideration pursuant
to the provisions of this <U>ARTICLE III</U>, and the Book-Entry Share or Certificate so
surrendered shall forthwith be cancelled. No interest shall be paid or accrued on the Merger
Consideration payable to holders of Book-Entry Shares or Certificates. If any Merger Consideration
is to be paid to a Person other than a Person in whose name the Book-Entry Share or Certificate
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">surrendered in exchange therefor is registered, it shall be a condition of such exchange that
the Person requesting such exchange present proper evidence of transfer and pay to the Paying Agent
any transfer or other Taxes required by reason of payment of the Merger Consideration to a Person
other than the registered holder of the Book-Entry Share or Certificate surrendered, or shall
establish to the reasonable satisfaction of the Paying Agent that such Tax has been paid or is not
applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Consideration Fund shall be invested by the Paying Agent as directed by Parent or the
Surviving Corporation. Earnings on the Consideration Fund shall be the sole and exclusive property
of Parent and the Surviving Corporation and shall be paid to Parent or the Surviving Corporation,
as Parent directs. No investment of the Consideration Fund shall relieve Parent, the Surviving
Corporation or the Paying Agent from making the payments required by this <U>ARTICLE III</U>, and
following any net losses from any such investment, Parent shall promptly provide additional funds
to the Paying Agent for the benefit of the applicable holders of Shares immediately prior to the
Effective Time in the amount of such net losses, which additional funds shall be deemed to be part
of the Consideration Fund. No investment of the Consideration Fund shall have maturities that
could prevent or delay payments to be made pursuant to this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;At and after the Effective Time, there shall be no transfers on the stock transfer books
of the Company of the Shares that were outstanding immediately prior to the Effective Time. If,
after the Effective Time, Certificates or Book-Entry Shares are presented to the Surviving
Corporation or the Paying Agent for any reason, they shall be cancelled and exchanged for the
Merger Consideration pursuant to this <U>ARTICLE III</U>, except as otherwise provided by Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Any portion of the Consideration Fund (including the proceeds of any investments thereof)
that remains unclaimed by the applicable former stockholders of the Company one (1)&nbsp;year after the
Effective Time shall be delivered to the Surviving Corporation. Any holders of Certificates or
Book-Entry Shares who have not theretofore complied with this <U>ARTICLE III</U> with respect to
such Certificates or Book-Entry Shares shall thereafter look only to the Surviving Corporation for
payment of their claim for Merger Consideration in respect thereof (if any).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Notwithstanding the foregoing, neither the Paying Agent nor any party hereto shall be
liable to any Person in respect of cash from the Consideration Fund delivered to a public official
pursuant to any applicable abandoned property, escheat or similar Law. If any Certificate or
Book-Entry Share shall not have been surrendered prior to the date on which any Merger
Consideration in respect thereof would otherwise escheat to or become the property of any
Governmental Entity, any such Merger Consideration in respect of such Certificate or Book-Entry
Share shall, to the extent permitted by applicable Law, become the property of the Surviving
Corporation, and any holder of such Certificate or Book-Entry Share who has not theretofore
complied
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">with this <U>ARTICLE III</U> with respect thereto shall thereafter look only to the Surviving
Corporation for payment of its claim for Merger Consideration in respect thereof (if any).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;If any Certificate shall have been lost, stolen or destroyed, upon the making of an
affidavit of that fact (such affidavit shall be in a form reasonably satisfactory to Parent and the
Paying Agent) by the Person claiming such Certificate to be lost, stolen or destroyed, and, if
required by Parent, the posting by such Person of a bond in such reasonable and customary amount as
Parent may direct as indemnity against any claim that may be made with respect to such Certificate,
the Paying Agent shall issue in exchange for such lost, stolen or destroyed Certificate the Merger
Consideration to which such Person is entitled in respect of such Certificate pursuant to this
<U>ARTICLE III</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Prior to the Effective Time, the Company shall take all steps reasonably necessary to
cause the transactions contemplated hereby and any other dispositions of equity securities of the
Company in connection with this Agreement by each individual who is subject to the reporting
requirements of Section 16(a) of the Exchange Act to be exempt under Rule&nbsp;16b-3 promulgated under
the Exchange Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Parent, Sub, the Surviving Corporation or the Paying Agent shall be entitled to deduct and
withhold from the consideration otherwise payable pursuant to this Agreement to any holder of
Shares or Company Options such amounts as Parent, Sub, the Surviving Corporation or the Paying
Agent is or may be reasonably required to deduct and withhold with respect to the making of such
payment under the Code, or any provision of state, local or foreign Tax Law. To the extent that
amounts are so withheld and paid over to the appropriate taxing authority by Parent, Sub, the
Surviving Corporation or the Paying Agent, such withheld amounts shall be treated for all purposes
of this Agreement as having been paid to the holder of the Shares or Company Options in respect of
which such deduction and withholding was made by Parent, Sub, the Surviving Corporation or the
Paying Agent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Notwithstanding anything stated to the contrary in this Agreement, it is agreed that no
deduction or withholding of any Israeli Income Tax shall be required or shall be made out of any
consideration payable pursuant to this Agreement to any holder of Shares or Company Options (except
for Company Options, Restricted Stock Awards or Company RSUs granted under the Israeli Equity
Plan), and no amount out of such consideration is required to be withheld and transferred or shall
be withheld and transferred to the ITA, in each of the following cases:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Payments to holders of Shares qualifying under Income Tax Regulations
(Tax Exemption for Foreign Residents on the Sale of Security) 5763-2003 in effect
as of the date of this Agreement; or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Payments to holders of Shares that are qualified residents of a
jurisdiction that has a dual income tax treaty with Israel providing for an
exemption in Israel from capital gains on a sale of Israeli assets.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In order for a holder of Shares or Company Options to qualify under Sections&nbsp;3.2(j)(i) or (ii)
above, a holder of Shares or Company Options must provide to Parent, Sub, the Surviving Corporation
or the Paying Agent a complete and accurate Tax Declaration in the form attached as Exhibit&nbsp;B
hereto on which Parent, Sub, the Surviving Corporation or the Paying Agent will rely.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.3 <U>Stock Options and Other Equity-Based Awards</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as set forth in <U>Section&nbsp;3.3(a)</U> of the Company Disclosure Schedule, each
option to purchase Shares granted under the Company&#146;s 1998 Stock Incentive Plan, the Company&#146;s 2004
Equity Incentive Plan, the Israeli Equity Plan and the Company&#146;s 2006 Equity Incentive Plan
(collectively, the &#147;<U>Equity Plans</U>&#148;), and options to purchase Shares granted outside a plan
and outstanding at the Effective Time, whether or not vested or exercisable (any such option,
whether granted under an Equity Plan or otherwise, a &#147;<U>Company Option</U>&#148;), shall at the
Effective Time be cancelled, and the holder of each such Company Option shall be entitled to
receive from the Company, as of the Effective Time and with respect to each such Company Option,
cash, without interest, equal to the product of (a)&nbsp;the excess, if any, of the Merger Consideration
over the exercise price per share of such Company Option, multiplied by (b)&nbsp;the number of Shares
covered by such Company Option (the aggregate amount of such cash, the &#147;<U>Option
Consideration</U>&#148;), with such payment to be subject to any applicable Tax withholding (in
accordance with Sections&nbsp;3.2(i) and (j)). For clarity, no Option Consideration shall be payable in
respect of Company Options with an exercise price per share in excess of the Merger Consideration.
Prior to the Initial Expiration Time and subject to the foregoing, the Company shall take all steps
requested by Parent to ensure that no holder of any Company Option shall have the right to acquire
any of the Surviving Corporation&#146;s equity securities (or other interests in respect thereof) at any
time following the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as set forth in <U>Section&nbsp;3.3(b)</U> of the Company Disclosure Schedule, (i)
restrictions on each restricted stock award granted under the Equity Plans and outstanding
immediately before the Effective Time (each, a &#147;<U>Restricted Stock Award</U>&#148;) shall lapse as of
the Effective Time and such Restricted Stock Award shall be treated in the same manner as other
Shares under <U>Section&nbsp;3.1</U>, subject to applicable Tax withholding and (ii)&nbsp;each restricted
stock unit award with respect to a Share granted under the Equity Plans and outstanding immediately
before the Effective Time (each, a &#147;<U>Company RSU</U>&#148;) shall be canceled, with the holder of
each such Company RSU becoming entitled to receive the Merger Consideration, subject to Tax
withholding.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding subsections (a)&nbsp;and (b)&nbsp;above, except as set forth in <U>Section
3.3(c)</U> of the Company Disclosure Schedule, with respect to holders of Company Options,
Restricted Stock Awards or Company RSUs held in trust under the Israeli Equity Plan at the
Effective Time, the Option Consideration or the Merger Consideration with respect to such Company
Options, Restricted Stock Awards or Company RSUs shall be paid directly to the Israeli Equity Plan
trustee (the &#147;<U>Trustee</U>&#148;). The Trustee shall, and the Company shall cause the Trustee to,
deduct from each payment of Option Consideration or Merger Consideration (as the case may be) the
applicable withholding Tax at the maximum rate required under Israeli Law and to transfer such
amount to the ITA, unless the Trustee shall have received, at least one (1)&nbsp;Business Day prior
to&nbsp;the last day on which the amounts so withheld must be transferred to the ITA, either (i)&nbsp;the
Israeli Tax Ruling in a form sufficient, under applicable Law, to the Trustee&#146;s satisfaction, to
establish that withholding is not required or that a lower withholding rate applies;
<U>provided</U> that the terms and conditioned of the Israeli Tax Ruling are met, or (ii)
certificates or forms issued by the ITA with respect to any or all holders of a Company Option, as
are sufficient, under applicable Law, to the Trustee&#146;s satisfaction, to establish that withholding
is not required or that a lower withholding rate applies, in which case, the Trustee shall
withhold, in lieu of the maximum rate referred to above, such amounts as are consistent with such
Israeli Tax Ruling, certificates or forms. To the extent that amounts are so withheld and paid
over to the ITA, such withheld amounts shall be treated for all purposes of this Agreement as
having been paid to the holder of the Company Options, Restricted Stock Awards or Company RSUs in
respect of which such deduction and withholding was made by the Trustee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Prior to the Initial Expiration Time, the Company shall use its reasonable efforts to
obtain an acknowledgment from each holder of the Warrants listed on Schedule&nbsp;3.3(d) of the Company
Disclosure Schedule which shall provide for the cancellation of all such Warrants as of the
Effective Time in return for a cash payment to each such holder (promptly following the Effective
Time) in an amount equal to (i)&nbsp;the product of (A)&nbsp;the number of Shares subject to the Warrants of
such holder and (B)&nbsp;the Merger Consideration <U>minus</U> (ii)&nbsp;the product of (A)&nbsp;the number of
Shares subject to the Warrants of such holder and (B)&nbsp;the per share exercise price of such Warrants
immediately prior to the Effective Time (provided that if the foregoing calculation results in a
negative number, the cash payment shall be $0). All amounts payable in respect of such Warrants
pursuant to this <U>Section&nbsp;3.3(d)</U> shall be subject to any required withholding of Taxes and
shall be paid without interest. Prior to the Initial Expiration Time and subject to the foregoing,
the Company shall take all steps necessary to ensure that no holder of Warrants shall have the
right to acquire any of the Surviving Corporation&#146;s equity securities (or other interests in
respect thereof) at any time following the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Prior to the Effective Time, the Company shall use its reasonable efforts to take all such
actions as may be required to effectuate the provisions of this <U>Section&nbsp;3.3</U> and to cause
the Equity Plans and all rights thereunder (other than the right to the Option Consideration and
Merger Consideration as provided herein) to be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">terminated effective as of the Effective Time. After the Effective Time, Parent shall provide
to the Surviving Corporation or the Paying Agent all funds necessary to fulfill the obligations
under this <U>Section&nbsp;3.3</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.4 <U>Dissenting Shares</U>. Notwithstanding <U>Section&nbsp;3.1(a)</U> hereof, to the
extent that holders thereof are entitled to appraisal rights under Section&nbsp;262 of the DGCL, Shares
issued and outstanding immediately prior to the Effective Time and held by a holder who has
properly exercised and perfected his or her demand for appraisal rights under Section&nbsp;262 of the
DGCL (the &#147;<U>Dissenting Shares</U>&#148;), shall not be converted into the right to receive the Merger
Consideration, but the holders of such Dissenting Shares shall be entitled to receive such
consideration as shall be determined pursuant to Section&nbsp;262 of the DGCL; <U>provided</U>,
<U>however</U>, that if any such holder shall have failed to perfect or shall have effectively
withdrawn or lost his or her right to appraisal and payment under the DGCL, such holder&#146;s Shares
shall thereupon be deemed to have been converted as of the Effective Time into the right to receive
the Merger Consideration, without any interest thereon, and such shares shall not be deemed to be
Dissenting Shares. The Company shall promptly provide Parent with notice of any demands for
appraisal of any Shares, and Parent shall have the right to participate in and direct all
negotiations and proceedings with respect to such demands. Prior to the Effective Time, the
Company shall not, without the prior written consent of Parent, voluntarily make any payment with
respect to, or settle or offer to settle, any such demands, or agree to do any of the foregoing.
Any payments required to be made with respect to the Dissenting Shares shall be made by Parent and
the aggregate Merger Consideration shall be reduced, on a dollar-for-dollar basis, as if the holder
of such Dissenting Shares had not been a stockholder of the Company immediately prior to the
Effective Time.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>REPRESENTATIONS AND WARRANTIES OF THE COMPANY</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as disclosed in the Company SEC Reports filed by the Company after January&nbsp;1, 2008 and
prior to the date of this Agreement (other than any disclosures therein under the caption &#147;Risk
Factors&#148; and any other disclosures therein of risks that are predictive or forward-looking in
nature) (such reports, the &#147;<U>Filed SEC Reports</U>&#148;) and, subject to <U>Section&nbsp;9.4</U>, except
as disclosed in the Company Disclosure Schedule, the Company represents and warrants to Parent and
Sub as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.1 <U>Organization</U>. Each of the Company and its Subsidiaries is duly organized,
validly existing and (to the extent applicable) in good standing under the laws of the jurisdiction
of its incorporation or organization and has the requisite corporate power and authority to own,
lease and operate its properties and to carry on its business as it is now being conducted, except
where the failure to be so existing and (to the extent applicable) in good standing or to have such
power and authority would not, individually or in the aggregate, have a Company Material Adverse
Effect. Each of the Company and its Subsidiaries is duly qualified or licensed to do business and
(to the extent applicable)
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">is in good standing in each jurisdiction in which the property leased or operated by it or the
nature of the business conducted by it makes such qualification or licensing necessary, except
where the failure to be so duly qualified, licensed and in good standing would not, individually or
in the aggregate, have a Company Material Adverse Effect. The Company has made available to Parent
a copy of its certificate of incorporation and bylaws and the organizational documents of each of
the Subsidiaries, as currently in effect, and neither the Company nor any of its Subsidiaries is in
violation of any provision of its certificate of incorporation, bylaws or other organizational
documents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.2 <U>Capitalization</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As of November&nbsp;20, 2008, the authorized capital stock of the Company consists of (i)
43,636,364 Shares, 17,130,332 of which were issued and outstanding and 1,090,909 of which were
reserved for issuance pursuant to the Equity Plans (including 942,475 reserved for issuance
pursuant to outstanding Company Options and 94,779 reserved for issuance pursuant to outstanding
restricted stock and Company RSUs) and of which 38,903 were reserved for issuance upon exercise of
the Warrants, and (ii)&nbsp;7,272,727 shares of preferred stock, par value $0.01 per share, none of
which were issued and outstanding. &#147;<U>Warrants</U>&#148; refer to the warrants identified on
<U>Section&nbsp;4.2(a)</U> of the Company Disclosure Schedule. All the outstanding shares of the
Company&#146;s capital stock are duly authorized, validly issued, fully paid, nonassessable and free of
preemptive rights. As of the date hereof, other than pursuant to the Equity Plans and the
Warrants, there are no existing (i)&nbsp;options, warrants, calls, subscriptions or other rights,
convertible securities, agreements or commitments of any character obligating the Company or any of
its Subsidiaries to issue, transfer or sell any shares of capital stock or other equity interest
in, the Company or securities convertible into or exchangeable for such shares or equity interests,
(ii)&nbsp;contractual obligations of the Company or any of its Subsidiaries to repurchase, redeem or
otherwise acquire any capital stock of the Company or (iii)&nbsp;voting trusts or similar agreements to
which the Company or any of its Subsidiaries is a party with respect to the voting of the capital
stock of the Company. The number of issued and outstanding Shares is subject to change before the
Effective Time, subject to compliance with the terms of <U>Section&nbsp;6.1(a)</U>, upon the exercise
of outstanding Company Options or settlement of outstanding Company RSUs pursuant to the Equity
Plans or the exercise of Warrants. <U>Section&nbsp;4.2(a)</U> of the Company Disclosure Schedule sets
forth a complete and accurate list, as of the date hereof, of (A)&nbsp;all Company Options and other
outstanding options to purchase Shares issued under Equity Plans or otherwise, the number of Shares
subject thereto, the grant dates, expiration dates, exercise or base prices (if applicable) and
vesting schedules thereof and the names of the holders thereof, (B)&nbsp;all Shares or other Share-based
awards that were outstanding but were subject to vesting or other forfeiture restrictions,
including Restricted Stock Awards and Company RSUs, or were subject to a right of repurchase by the
Company at a fixed purchase price as of such time under Equity Plans or otherwise, the grant and
issuance dates, vesting schedules and repurchase price (if any) thereof and the names of the
holders thereof and (C)&nbsp;all outstanding warrants to purchase Shares, the number of Shares subject
thereto, the grant dates, expiration dates, exercise price and vesting schedules thereof (if any)
and the names of the holders thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Section&nbsp;4.2(b)</U> of the Company Disclosure Schedule lists as of the date hereof each
of the Subsidiaries of the Company and, for each Subsidiary, the jurisdiction of incorporation or
formation. Each of the outstanding shares of capital stock, voting securities or other equity
interests of each Subsidiary of the Company is duly authorized, validly issued, fully paid,
nonassessable and free of any preemptive rights, and all such securities are owned by the Company
or another wholly owned Subsidiary of the Company and are owned free and clear of all liens.
Except for the Top-Up Option, there are no (i)&nbsp;outstanding options or other rights of any kind
which obligate the Company or any of its Subsidiaries to issue or deliver any shares of capital
stock, voting securities or other equity interests of any such Subsidiary or any securities or
obligations convertible into or exchangeable into or exercisable for any shares of capital stock,
voting securities or other equity interests of a Subsidiary of the Company, (ii)&nbsp;outstanding
obligations of the Company or any of its Subsidiaries to repurchase, redeem or otherwise acquire
any securities or obligations convertible into or exchangeable into or exercisable for any shares
of capital stock, voting securities or other equity interests of a Subsidiary of the Company or
(iii)&nbsp;other options, calls, warrants or other rights, agreements, arrangements or commitments of
any character relating to the issued or unissued capital stock of any Company Subsidiary to which
the Company or any of its Subsidiaries is a party. Each grant of a Company Option was duly
authorized no later than the date on which the grant of such Company Option was by its terms to be
effective (the &#147;<U>Grant Date</U>&#148;)<SUP style="font-size: 85%; vertical-align: text-top"> </SUP>by all necessary corporate action, including, as
applicable, approval by the Board of Directors of the Company (or a duly constituted and authorized
committee thereof) and any required stockholder approval by the necessary number of votes or
written consents, each such grant is governed by an award agreement duly executed and delivered by
each party thereto, copies of each such award agreement (or indicative forms in the case of
unvaried standard award agreements) have been made available to Parent, each such grant was made
pursuant to and in accordance with the terms of an Equity Plan, the Exchange Act and all other
applicable laws and regulatory rules or requirements, the per share exercise price of each Company
Option was equal to the fair market value (within the meaning of Section&nbsp;422 of the Code, in the
case of each Company Option intended to qualify as an &#147;incentive stock option&#148;, and within the
meaning of Section&nbsp;409A of the Code, in the case of each other Company Option) of one Share on the
applicable Grant Date. The Company has not knowingly granted, and there is not and has not been
any Company policy or practice to knowingly grant, Company Options prior to, or otherwise knowingly
coordinate the grant of Company Options with, the release or other public announcement of material
information regarding the Company or its Subsidiaries or their financial results or prospects.
Each Restricted Stock Award and Company RSU may, by its terms, be treated at the Effective Time as
set forth in <U>Section&nbsp;3.3</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.3 <U>Authorization; Validity of Agreement; Company Action</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company has the requisite corporate power and authority to execute and deliver this
Agreement and, subject to obtaining the Company Stockholder Approval if required by applicable Law,
to consummate the Merger, to perform its obligations hereunder and to consummate the transactions
contemplated by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">this Agreement. The execution, delivery and performance by the Company of this Agreement, and
the consummation by it of the transactions contemplated by this Agreement, have been duly
authorized and approved by all necessary corporate action on the part of the Company (including by
its Board of Directors), and except for the Company Stockholder Approval, if required by applicable
Law to consummate the Merger, no other corporate action or proceeding on the part of the Company is
necessary to authorize the execution, delivery and performance by the Company of this Agreement and
the consummation by it of the transactions contemplated by this Agreement. This Agreement has been
duly executed and delivered by the Company and, assuming due authorization, execution and delivery
of this Agreement by the other parties hereto, constitutes a legal, valid and binding obligation of
the Company, enforceable against the Company in accordance with its terms, except that (i)&nbsp;such
enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or
other similar Laws, now or hereafter in effect, affecting creditors&#146; rights and remedies generally
and (ii)&nbsp;the remedy of specific performance and injunctive and other forms of equitable relief may
be subject to equitable defenses and to the discretion of the court before which any proceeding
therefor may be brought.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.4 <U>Consents and Approvals; No Violations</U>. Except for (a)&nbsp;filings pursuant to the
Israeli Anti-Trust Law or any other required antitrust filings and the receipt, termination or
expiration, as applicable, of approvals or waiting periods required under any applicable
competition, merger control, antitrust or similar Law, (b)&nbsp;the filing of customary applications and
notices, as applicable, with the FDA, EMEA or any other federal, state, local or foreign Regulatory
Authority, (c)&nbsp;applicable requirements of and filings with the SEC under the Exchange Act, (d)
filings with The Nasdaq Global Market, Inc., (e)&nbsp;the filing of the Certificate of Merger, (f)
applicable requirements under corporation or &#147;blue sky&#148; laws of various states, (g)&nbsp;the filing
pursuant to the Law for the Encouragement of Capital Investment, 5719-1959, and the regulations and
approvals promulgated thereunder and (h)&nbsp;the filing pursuant to the Encouragement of Industrial
Research and Development Law, 5744-1984, and the regulations and grant approvals promulgated
thereunder by the Office of the Chief Scientist in the Israeli Ministry of Industry, Trade &#038; Labor
(&#147;<U>OCS</U>&#148;), neither the execution, delivery or performance of this Agreement by the Company
nor the consummation by the Company of the transactions contemplated hereby will (i)&nbsp;violate any
provision of the certificate of incorporation or bylaws of the Company, (ii)&nbsp;result in a violation
or breach of, or constitute (with or without due notice or lapse of time or both) a default (or
give rise to any right of termination, cancellation or acceleration) under, any of the terms,
conditions or provisions of any note, bond, mortgage, indenture, lease, license, contract,
agreement, Company Permit or other instrument or obligation to which the Company is a party or by
which it or any of its properties or assets may be bound, (iii)&nbsp;violate any Law applicable to the
Company or any of its properties or assets or (iv)&nbsp;require on the part of the Company any material
filing or registration with, notification to, or authorization, consent or approval of, any court,
legislative, executive or regulatory authority or agency (whether domestic or foreign) (a
&#147;<U>Governmental Entity</U>&#148;); except in the case of clauses (ii)&nbsp;and (iii)&nbsp;for such violations,
breaches, defaults, terminations, cancellations or accelerations the failure of which to make or
obtain (A)&nbsp;would not, individually or in the aggregate, (x)&nbsp;have a Company Material Adverse Effect
and (y)
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">reasonably be expected to prevent or materially impede, interfere with, hinder or delay the
consummation by the Company of the transactions contemplated by this Agreement or (B)&nbsp;would occur
or be required as a result of the business or activities in which Parent or Sub is or proposes to
be engaged or as a result of any acts or omissions by, or the status of any facts pertaining to,
Parent or Sub.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.5 <U>SEC Reports</U>. The Company has filed all reports and proxy statements with the
SEC required to be filed by the Company since January&nbsp;1, 2007 (as such reports and statements may
have been amended since the date of their filing, the &#147;<U>Company SEC Reports</U>&#148;). As of their
respective filing dates or the filing dates of amendments, the Company SEC Reports (i)&nbsp;complied in
all material respects with, to the extent in effect at the time of filing, the applicable
requirements of the Securities Act and the Exchange Act and (ii)&nbsp;did not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or
necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. Each of the financial statements (including the related notes) of the
Company included in the Company SEC Reports complied at the time it was filed as to form in all
material respects with the applicable accounting requirements and the published rules and
regulations of the SEC with respect thereto in effect at the time of such filing, was prepared in
accordance with generally accepted accounting principles in the United States (&#147;<U>GAAP</U>&#148;)
(except, in the case of unaudited statements, as permitted by the rules and regulations of the SEC)
applied on a consistent basis during the periods involved (except as may be indicated in the notes
thereto) and fairly presented in all material respects the consolidated financial position of the
Company and its consolidated Subsidiaries as of the respective dates thereof and the consolidated
results of their operations and cash flows for the respective periods then ended (subject, in the
case of unaudited statements, to normal year-end adjustments). The Company has complied and is in
compliance in all material respects with all applicable certification, internal control and other
requirements and provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations
promulgated thereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.6 <U>No Undisclosed Liabilities</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except for (i)&nbsp;liabilities and obligations incurred in the ordinary course of business
since December&nbsp;31, 2007, (ii)&nbsp;liabilities and obligations disclosed in the Filed SEC Reports, (iii)
liabilities and obligations incurred in connection with the transactions contemplated by this
Agreement and (iv)&nbsp;liabilities and obligations that would not, individually or in the aggregate,
have a Company Material Adverse Effect, since December&nbsp;31, 2007, neither the Company nor any of its
Subsidiaries has incurred any liabilities or obligations of any nature (whether accrued, absolute,
contingent or otherwise).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the Company nor any of its Subsidiaries is a party to, or has any commitment to
become a party to, any joint venture, off balance sheet partnership or any similar contract or
arrangement where the result, purpose or intended
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">effect thereof is to avoid disclosure of any material transaction involving, or material
liabilities of, the Company or any of its Subsidiaries in the Company&#146;s or such Subsidiary&#146;s
published financial statements or other Company SEC Reports.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Since January&nbsp;1, 2007, the Company has not received any oral or written notification of
any (x) &#147;significant deficiency&#148; or (y) &#147;material weakness&#148; in the Company&#146;s internal control over
financial reporting. There is no outstanding &#147;significant deficiency&#148; or &#147;material weakness&#148; which
the Company&#146;s independent accountants certify has not been appropriately and adequately remedied by
the Company. For purposes of this Agreement, the terms &#147;significant deficiency&#148; and &#147;material
weakness&#148; shall have the meanings assigned to them in Release 2004-001 of the Public Company
Accounting Oversight Board, as in effect on the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.7 <U>Absence of Certain Changes</U>. Except for liabilities incurred in connection with
this Agreement and except as expressly permitted or contemplated by this Agreement, since December
31, 2007 the Company and its Subsidiaries have conducted their respective businesses only in the
ordinary course consistent with past practice, and the Company has not suffered a Company Material
Adverse Effect, and since December&nbsp;31, 2007 until the date hereof there has not been (i)&nbsp;any
declaration, setting aside or payment of any dividend or other distribution (whether in cash, stock
or property) with respect to any capital stock of the Company or any of its Subsidiaries, other
than any declaration setting aside or payment from a wholly owned Subsidiary of the Company to the
Company, (ii)&nbsp;any purchase, redemption or other acquisition by the Company or any of its
Subsidiaries of any shares of capital stock or any other securities of the Company or any of its
Subsidiaries or any options, warrants, calls or rights to acquire such shares or other securities
(other than acquisitions of Shares in connection with the surrender of Shares by holders of Company
Options or Warrants in order to pay the exercise price thereof), (iii)&nbsp;any split, combination or
reclassification of any capital stock of the Company or any of its Subsidiaries or any issuance or
the authorization of any issuance of any other securities in respect of, in lieu of or in
substitution for shares of their respective capital stock, (iv) (A)&nbsp;any granting by the Company or
any of its Subsidiaries to any Specified Participant of any increase in compensation, bonus or
fringe or other benefits or any granting of any type of compensation or benefits to any Specified
Participant not previously receiving or entitled to receive such type of compensation or benefit,
except as was required under any agreement or Benefit Plan in effect as of December&nbsp;31, 2007, (B)
any granting by the Company or any of its Subsidiaries to any director, officer, employee or
consultant of any right to receive, or any increase in, change of control, retention, severance or
termination compensation or benefits, (C)&nbsp;any entry by the Company or any of its Subsidiaries into,
or any amendment or termination of (1)&nbsp;any employment, deferred compensation, consulting,
severance, change of control, termination, retention, indemnification, loan or similar agreement
between the Company or any of its Subsidiaries, on the one hand, and any Specified Participant, on
the other hand, or (2)&nbsp;any agreement between the Company or any of its Subsidiaries, on the one
hand, and any Specified Participant, on the other hand, the benefits of which are contingent, or
the terms of which are materially altered, upon the occurrence of a transaction involving the
Company of a nature contemplated by this Agreement (all such
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">agreements under this clause (C), collectively, &#147;<U>Specified Benefit Agreements</U>&#148;), (D)&nbsp;any
payment of any compensation or benefit under, or the grant of any award under, any bonus,
incentive, performance or other compensation plan or arrangement, Specified Benefit Agreement,
Equity Plan or Benefit Plan, except as required to comply with applicable Law or any Specified
Benefit Agreement, Equity Plan or Benefit Plan in effect as of December&nbsp;31, 2007, (E)&nbsp;the taking of
any action to fund or in any other way secure the payment of compensation or benefits under any
Equity Plan, Benefit Plan or Specified Benefit Agreement (except as required by a Benefit Plan as
in effect on December&nbsp;31, 2007) or (F)&nbsp;the taking of any action to accelerate the vesting or
payment of any compensation or benefits under any Equity Plan, Benefit Plan or Specified Benefit
Agreement, (v)&nbsp;any damage, destruction or loss to any asset of the Company or any of its
Subsidiaries, whether or not covered by insurance, that individually or in the aggregate would have
a Company Material Adverse Effect, (vi)&nbsp;any change in accounting methods, principles or practices
by the Company materially affecting its assets, liabilities or businesses, except insofar as may
have been required by a change in GAAP or (vii)&nbsp;except with respect to depreciation and
amortization of the assets of the Company or any of its Subsidiaries, any material Tax election or
change in such election, any change in material method of accounting for Tax purposes or any
settlement or compromise of any material income Tax liability. Since December&nbsp;31, 2007, neither
the Company nor any of its Subsidiaries have incurred indebtedness.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.8 <U>Employee Benefit Plans; ERISA</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Section&nbsp;4.8(a)</U> of the Company Disclosure Schedule sets forth a list, as of the
date hereof and except as required by Israeli Severance Pay Law 1963, of each deferred
compensation, bonus or other incentive compensation, stock purchase, stock option and other equity
compensation plan, program, agreement or arrangement; each severance or termination pay, medical,
surgical, hospitalization, life insurance and other &#147;welfare&#148; plan, fund or program (within the
meaning of Section&nbsp;3(1) of the Employee Retirement Income Security Act of 1974 (&#147;<U>ERISA</U>&#148;));
each profit-sharing, stock bonus or other &#147;pension&#148; plan, fund or program (within the meaning of
Section&nbsp;3(2) of ERISA); each employment, termination, change in control, retention or severance
agreement; and each other employee benefit plan, fund, program, agreement or arrangement, in each
case, that is sponsored, maintained or contributed to or required to be contributed to by the
Company or by any trade or business, whether or not incorporated, that together with the Company
would be deemed a &#147;single employer&#148; within the meaning of Section 4001(b) of ERISA (any such trade
or business, an &#147;<U>ERISA Affiliate</U>&#148;), or to which the Company or an ERISA Affiliate is party
for the benefit of any Employee (the &#147;<U>Benefit Plans</U>&#148;). The Company has made available to
Parent a true and complete copy of each Benefit Plan and all amendments thereto (or, in the case of
any unwritten Benefit Plans, descriptions thereof) and a true and complete copy of the following
items (in each case, only if applicable): (i)&nbsp;each trust or other funding arrangement, (ii)&nbsp;each
summary plan description and summary of material modifications, (iii)&nbsp;the most recently filed
annual report on IRS Form&nbsp;5500, (iv)&nbsp;the most recently received IRS determination letter and (v)
any filings made with the ITA with respect to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">each Benefit Plan and any notices of the ITA and other correspondence with the ITA, in this
regard.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Benefit Plan is now and has been operated in all material respects in accordance with
the requirements of all applicable Laws of the relevant jurisdiction, including ERISA and the Code,
and in accordance with its terms. None of the Company or any ERISA Affiliate has engaged in any
transactions that are reasonably expected to result in the imposition of material penalties
pursuant to Section 502(i) of ERISA, material damages pursuant to Section&nbsp;409 of ERISA or a
material Tax pursuant to Section&nbsp;4975 of the Code. All contributions, premiums and benefit
payments under or in connection with the Benefit Plans that are required to have been made as of
the date hereof in accordance with the terms of the Benefit Plans have been timely made or have
been reflected on the most recent consolidated balance sheet filed or incorporated by reference
into the Company SEC Reports. The Company does not have any material liability to the ITA with
respect to any Benefit Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each Benefit Plan intended to qualify under Section 401(a) of the Code has either received
a favorable determination letter from the IRS with respect to each such Benefit Plan as to its
qualified status under the Code, or with respect to a prototype Benefit Plan, the prototype sponsor
has received a favorable IRS opinion letter, or the Benefit Plan or prototype sponsor has remaining
a period of time under applicable treasury regulations of the Code or pronouncements of the IRS in
which to apply for such a letter and make any amendments necessary to obtain a favorable
determination or opinion as to the qualified status of each such Benefit Plan. No such
determination or opinion letter has been revoked (nor, to the knowledge of the Company, has
revocation been threatened) and no event has occurred since the most recent determination or
opinion letter or application therefor relating to any such Benefit Plan that would reasonably be
expected to adversely affect the qualification of such Benefit Plan or materially increase the
costs relating thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;With respect to each Benefit Plan that is not a &#147;multiemployer plan&#148; within the meaning of
Section&nbsp;3(37) of ERISA, (i)&nbsp;no liability under Title IV or Section&nbsp;302 of ERISA or Section&nbsp;412 of
the Code has been incurred by the Company or any ERISA Affiliate that has not been satisfied in
full (ii)&nbsp;to the knowledge of the Company, no condition exists that presents a material risk to the
Company or any ERISA Affiliate of incurring a material liability under Title IV of ERISA and (iii)
the Pension Benefit Guaranty Corporation has not instituted proceedings under Section&nbsp;4042 of ERISA
to terminate any Benefit Plan and, to the knowledge of the Company, no condition exists that
presents a material risk that such proceedings will be instituted. None of the employees of the
Company or any of its Subsidiaries participate in any multiemployer pension or retirement plan (as
defined under applicable local Law), or any pension or retirement plan sponsored by any union or
similar employee representative or sponsored by more than one unrelated employer.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;There are no material unresolved claims or disputes under the terms of, or in connection
with, any Benefit Plan (other than routine undisputed claims for benefits), and, as of the date
hereof, no action, legal or otherwise, has been commenced with respect to any such material claim.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;No amounts payable under any Benefit Plan shall fail to be deductible for federal income
Tax purposes by virtue of Section&nbsp;280G of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Neither the execution and delivery of this Agreement nor the consummation of the
transactions contemplated hereby (either alone or in combination with another event) will, (i)
entitle any Participant to severance, change in control or retention pay, unemployment compensation
or any other payment or benefit, (ii)&nbsp;accelerate the time of payment or vesting, trigger any
payment or funding (through a grantor trust or otherwise) of, compensation or benefits under, or
increase the amount payable or trigger any material obligation to any Participant, or (iii)&nbsp;result
in any breach or violation of, or a default under, any Benefit Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Neither the Company nor any of its Subsidiaries has any material obligations for retiree
health or life insurance benefits under any Benefit Plan (other than for continuation coverage
required to be provided pursuant to Section&nbsp;4980B of the Code).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Except as expressly permitted pursuant to <U>Section&nbsp;6.1</U>, since December&nbsp;31, 2007,
there has not been any adoption, amendment or termination by the Company or any of its Subsidiaries
of any Benefit Plan, or any changes in any assumptions used to calculate funding obligations with
respect to any Benefit Plan, or any change in the manner in which contributions to any Benefit Plan
are made or the basis on which such contributions are determined, other than amendments or changes
required to ensure that such Benefit Plan is not then out of compliance with applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.9 <U>Litigation</U>. There is no suit, action or proceeding pending or, to the
knowledge of the Company, threatened against the Company or any of its Subsidiaries or any of their
respective assets that, individually or in the aggregate, would have a Company Material Adverse
Effect, nor is there any judgment, decree, injunction, rule or order of any Governmental Entity or
arbitrator outstanding against, or, to the knowledge of the Company, investigation by any
Governmental Entity involving, the Company or any of its Subsidiaries or any of their respective
assets that, individually or in the aggregate, would have a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.10 <U>Permits; Compliance with Law</U>. Each of the Company and each Subsidiary of the
Company is in possession of all material authorizations, licenses, permits, certificates, approvals
and clearances of, and has submitted all material notices to, all Governmental Entities necessary
to carry on its respective business as it is being conducted as of the date hereof, including all
authorizations under the regulations of the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">FDCA and the regulations of the FDA promulgated thereunder and any of the foregoing required by any
other Regulatory Authority (the &#147;<U>Company Permits</U>&#148;), and all such material Company Permits
are valid, and in full force and effect. Neither the Company nor any Subsidiary of the Company is
in violation of (i)&nbsp;any material Law applicable to it or by which any of its property or assets is
bound or affected or (ii)&nbsp;any material Company Permits. Notwithstanding the foregoing, this
<U>Section&nbsp;4.10</U> shall not apply to employee benefit matters, Taxes, Environmental Laws or
labor matters, which are the subject exclusively of the representations and warranties in
<U>Section&nbsp;4.8</U>, <U>Section&nbsp;4.12</U>, <U>Section&nbsp;4.14</U>, and <U>Section&nbsp;4.15</U>,
respectively.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.11 <U>Regulatory Matters</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;All manufacturing, processing, distribution, labeling, storage, testing, specifications,
sale or marketing of products performed by or on behalf of the Company or its Subsidiaries are in
compliance in all material respects with all applicable Laws administered or issued by any
Regulatory Authority, including FDA regulations for (i)&nbsp;Good Manufacturing Practices contained in
Title 21 part 606 of the Code of Federal Regulations and (ii)&nbsp;Medical Device Quality Systems
contained in Title 21 part 820 of the Code of Federal Regulations. None of the Company or any of
its Subsidiaries has at any time promoted any &#147;off label&#148; use of its Products.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;All pre-clinical and clinical investigations conducted or sponsored by the Company or any
of its Subsidiaries are being conducted in compliance in all material respects with all applicable
Laws administered or issued by the applicable Regulatory Authority, including (to the extent
applicable) (i)&nbsp;FDA standards for conducting non-clinical laboratory studies contained in Title 21
part 58 of the Code of Federal Regulations, (ii)&nbsp;investigational new drug requirements, (iii)&nbsp;FDA
standards for the design, conduct, performance, monitoring, auditing, recording, analysis and
reporting of clinical trials contained in Title 21 parts 50, 54, 56, 312, 314, and 320 of the Code
of Federal Regulations, (iv)&nbsp;federal and state Laws restricting the use and disclosure of
individually identifiable health information and (v)&nbsp;the International Conference on Harmonisation
Guideline on Good Clinical Practice (ICH Topic E6). Neither the Company nor any of its
Subsidiaries has received any written information from the FDA or the EMEA which would reasonably
be expected to lead to the denial of any application for marketing approval currently pending
before the FDA or the EMEA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Neither the Company nor any of its Subsidiaries has received any oral or written
communication (including any warning letter, untitled letter, Form&nbsp;483 or similar notice) from the
FDA or the EMEA, and to the Company&#146;s knowledge there is no action or proceeding pending or
threatened (including any prosecution, injunction, seizure, civil fine, suspension or recall), in
each case alleging that the Company or any of its Subsidiaries is not currently in compliance with
any material Law administered or issued by any Regulatory Authority. There are no pending
voluntary or involuntary market withdrawals, field corrective actions (including recalls),
destruction
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">orders, seizures or other regulatory enforcement actions related to any of the Company&#146;s
material products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Neither the Company nor any of its Subsidiaries has received any correspondence from the
FDA regarding, and, to the Company&#146;s knowledge, there is no pending or threatened action or
proceeding against, the Company or any of its Subsidiaries or any of its employees regarding any
material debarment action or investigation undertaken pursuant to the Generic Drug Enforcement Act
of 1992 (21 U.S.C. Sections&nbsp;335(a), (b)&nbsp;and (c)), or any similar regulation of the FDA or the EMEA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;To the Company&#146;s knowledge, no data generated by the Company or any of its Subsidiaries
with respect to their products that has been provided to its customers or otherwise made public is
the subject of any regulatory or other action, either pending or threatened, by any Regulatory
Authority relating to the truthfulness or scientific adequacy of such data.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;No product manufactured and/or distributed by the Company or any of its Subsidiaries is
(A)&nbsp;adulterated within the meaning of 21 U.S.C. &#167; 351 (or any similar Law), (B)&nbsp;misbranded within
the meaning of 21 U.S.C. &#167; 352 (or any similar Law) or (C)&nbsp;a product that is in violation of 21
U.S.C. &#167;&#167; 360 or 360e (or any similar Law).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Neither the Company nor any of its Subsidiaries, nor, to the knowledge of the Company, any
officer, employee, agent or distributor of the Company or any of its Subsidiaries, has made an
untrue statement of a material fact or a fraudulent statement to the FDA or any other Governmental
Entity, failed to disclose a material fact required to be disclosed to the FDA or any other
Governmental Entity, or committed an act, made a statement, or failed to make a statement that, at
the time such disclosure was made, would reasonably be expected to provide a basis for the FDA or
any other Governmental Entity to invoke its policy respecting &#147;Fraud, Untrue Statements of Material
Facts, Bribery, and Illegal Gratuities&#148;, set forth in 56 Fed. Reg. 46191 (September&nbsp;10, 1991) or
any similar policy. Neither the Company nor any of its Subsidiaries, nor, to the knowledge of the
Company, any officer, employee or agent of the Company or any of its Subsidiaries, has been
convicted of any crime or engaged in any conduct for which debarment is mandated by 21 U.S.C. &#167;
335a(a) or any similar Law or authorized by 21 U.S.C. &#167; 335a(b) or any similar Law. Neither the
Company nor any of its Subsidiaries, nor, to the knowledge of the Company, any officer, employee or
agent of the Company or any of its Subsidiaries, has been convicted of any crime or engaged in any
conduct for which such person or entity could be excluded from participating in the Federal health
care programs under Section&nbsp;1128 of the Social Security Act of 1935, as amended, or any similar
Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.12 <U>Taxes</U>.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Each of the Company and its Subsidiaries has (i)&nbsp;timely filed all Tax Returns required to
be filed by it (taking into account applicable extensions) and all such returns were true, correct
and complete in all material respects when filed and (ii)&nbsp;paid or accrued (in accordance with GAAP)
all material Taxes required to be paid on such Tax Returns other than such Taxes as are being
contested in good faith by the Company or any of its Subsidiaries, have not been finally determined
and have been adequately reserved against in accordance with GAAP.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;There are no ongoing federal, state, local or foreign audits or examinations of any Tax
Return of the Company or any of its Subsidiaries for which a written notice has been received by
the Company or any of its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There are no outstanding written requests, agreements, consents or waivers to extend the
statutory period of limitations applicable to the assessment of any material Taxes or deficiencies
against the Company or any of its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Neither the Company nor any of its Subsidiaries is a party to any agreement providing for
the allocation or sharing of Taxes or an agreement providing for an indemnification for Taxes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;There are no material liens for Taxes upon the assets of the Company or any of its
Subsidiaries that are not provided for in the financial statements included in the Company SEC
Reports, except liens for Taxes not yet due and payable and liens for Taxes that are being
contested in good faith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Company and its Subsidiaries have complied with all applicable statutes, Laws,
ordinances, rules and regulations relating to the payment and withholding of any amount of Taxes
(including withholding of Taxes pursuant to Sections&nbsp;1441, 1442, 3121 and 3402 of the Code and
similar provisions under any federal, state, local or foreign Tax Laws) and have, within the time
and manner prescribed by Law, withheld and paid over to the proper governmental authorities all
amounts required to be so withheld and paid over under applicable Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;No written claim has been made by any taxing authority in a jurisdiction where any of the
Company or its Subsidiaries does not file a Tax Return that it is or may be subject to taxation by
that jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Since December&nbsp;31, 2007, neither the Company nor its Subsidiaries has incurred any
liability for Taxes arising from extraordinary gains or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">losses, as that term is used in U.S. GAAP,
outside the ordinary course of business consistent with past custom and practice.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Each of the Company and its Subsidiaries has disclosed on its income Tax Returns all
positions taken therein that could give rise to a penalty if not disclosed, including but not
limited to all positions taken that could give rise to a substantial understatement of federal
income Tax under Section&nbsp;6662 of the Code or similar provision or other penalty under any federal,
state, local or foreign Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Neither the Company nor any of its Subsidiaries has been a member of any affiliated group
filing a consolidated federal income Tax Return (other than any such group the common parent of
which was the Company). Neither the Company nor any of its Subsidiaries is presently liable for
the Taxes of any other Person by reason of Treasury Regulations Section&nbsp;1.1502-6 (or any similar
provision of state, local or foreign Law), as a transferee or successor, by contract, indemnity or
otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;Neither the Company nor any of its Subsidiaries will be required to include any item of
income in, or exclude any item of deduction from, taxable income for any taxable period ending
after the Closing Date as a result of any: (i)&nbsp;adjustment pursuant to Section&nbsp;481 of the Code (or
similar provision under any federal, state, local or foreign Law) associated with a change of
accounting method that is effective on or before the date of this Agreement; (ii)&nbsp;closing agreement
or other agreement with any taxing authority executed on or before the date of this Agreement;
(iii)&nbsp;transaction entered into on or before the date of this Agreement and treated under the
installment method, long-term contract method, cash method, or open transaction method of
accounting or (iv)&nbsp;inclusion, other than in the ordinary course of business, under Section 951(a)
of the Code or similar provision of state, local or foreign Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;The Company and its Subsidiaries have properly and timely documented their transfer
pricing methodology for purposes of Section&nbsp;482 of the Code (or similar provision under any
federal, state, local or foreign Law).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;Neither the Company nor any of its Subsidiaries has participated in a &#147;reportable
transaction&#148; (within the meaning of Treasury Regulations Section&nbsp;1.6011-4(b) or similar provision
under any federal, state, local or foreign Law).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;Neither the Company nor any of its Subsidiaries has distributed the stock of another
Person, or had its stock distributed by another Person, in a transaction that was intended to be
governed in whole or in part by Section&nbsp;355 of the Code.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;Neither the Company nor any of its Subsidiaries has been a United States real property
holding corporation within the meaning of Section&nbsp;897(c)(2) of the Code during the applicable
period specified in Section&nbsp;897(c)(1)(A)(ii) of the Code.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;Neither the Company nor any of its Subsidiaries has applied for and not yet received a
ruling or determination from a taxing authority regarding a past or prospective transaction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;The Company and each Subsidiary has possession, custody or control of all records and
documentation that it is obliged to hold, preserve and retain for the purposes of any Tax and
sufficient information to enable it to compute correctly its liability for Tax in so far as it
relates to any event occurring on or before the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;The Company and each of its Subsidiaries (including, but not limited to, Omrix
Biopharmaceuticals, S.A., Biopex, Ltd., Omrix Biopharmaceuticals, Ltd., Omrix Biopharmaceuticals,
GmbH and Omrix Biopharmaceuticals (Asia) Ltd.) are currently, and have always been, treated as
corporations as defined in Treasury Regulations Sections&nbsp;301.7701-2 and 301.7701-3 (or any similar
definition in any applicable foreign Law).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(s)&nbsp;Neither the Company nor any of the Subsidiaries is a party to an agreement with any taxing
authority providing for any Tax incentives, credits, inducements or similar benefits, nor is any of
them otherwise participating in or claiming benefits under such a program.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(t) <U>Section&nbsp;4.12(t)</U> of the Company Disclosure Schedule lists each material Tax
incentive granted to or enjoyed by Company or any of its Subsidiaries under the Laws of the State
of Israel, the period for which such Tax incentive applies, and the nature of such Tax incentive.
The Company and its Subsidiaries are in compliance in all material respects with all conditions and
requirements stipulated by the instruments of approval granted to it with respect to any &#147;Approved
Enterprise&#148; status of any of the Company&#146;s or its Subsidiaries&#146; facilities under the Law for the
Encouragement of Capital Investment, 5719-1959 and the regulations and approvals promulgated
thereunder. Subject to receipt of the Investment Center of the Israeli Ministry of Industry,
Trade&nbsp;&#038; Labor approval, neither the acceptance for payment of Shares pursuant to the Offer nor the
consummation of the Merger will adversely affect the continued qualification for such incentives or
the terms or duration thereof or require any recapture of any previously claimed incentive
(including any &#147;Approved Enterprise&#148; status, any Tax exemptions, Tax holiday or other Tax
reductions), and no consent or approval of any Governmental Entity is required, other than the
Investment Center approval, in order to preserve the entitlement to any such incentive. The Company
and its Subsidiaries has not received any
notice of any proceeding or investigation relating to revocation or modification of any
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;Approved Enterprise&#148; status granted with respect to any of the Company&#146;s and its Subsidiaries&#146;
facilities which could reasonably be expected to result in material liability to the Company or its
Subsidiaries. All information supplied by the Company and its Subsidiaries with respect to the
applications relating to such &#147;Approved Enterprise&#148; status was true, correct and complete in all
material respects when submitted to the appropriate authorities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(u)&nbsp;The Company and its Subsidiaries are not subject to any restrictions or limitations
pursuant to Part&nbsp;E2 of the Israeli Income Tax Ordinance (New Version), 1961.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.13 <U>Intellectual Property</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company or its Subsidiaries own, license, or otherwise have the right to use all
Intellectual Property Rights that are necessary for the conduct of the business of the Company and
its Subsidiaries as currently conducted (the &#147;<U>Company Intellectual Property Rights</U>&#148;) free
and clear of all pledges, liens and security interests of any kind whatsoever, subject, with
respect to the Intellectual Property Rights set forth in <U>Section&nbsp;4.13(h)</U> of the Company
Disclosure Schedule, to the restrictions specified in <U>Section&nbsp;4.13(h)</U> of the Company
Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;To the knowledge of the Company, neither the Company nor any of its Subsidiaries has
infringed or is infringing (including with respect to the development, clinical testing,
manufacture, distribution, marketing, use or sale by the Company or any of its Subsidiaries of
their respective products the rights of any person with regard to any Intellectual Property Right
in a manner which, individually or in the aggregate, has resulted or would reasonably be expected
to result in a material liability to the Company or any of its Subsidiaries. To the knowledge of
the Company, no person or persons has infringed or is or are infringing any Company Intellectual
Property Rights that are material to the Company and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There are no pending or, to the knowledge of the Company, threatened claims that the
Company or any of its Subsidiaries has infringed or is infringing (including with respect to the
manufacture, use, distribution, marketing, or sale by the Company or its Subsidiaries of any
products or to the operations of the Company or its Subsidiaries) any Intellectual Property Rights
of any Person which would, individually or in the aggregate, have a Company Material Adverse
Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule sets forth, as of the date
hereof, a complete and accurate list of all patents and applications
therefor, registered Trademarks, Trademark applications and domain name registrations that, in
each case, are (i)&nbsp;owned by or licensed to the Company or any of its Subsidiaries or (ii)&nbsp;used to
conduct the business of the Company and its Subsidiaries as currently
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">conducted. All patents and
patent applications listed in <U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule are either
(a)&nbsp;owned by, or are subject to an obligation of assignment to, the Company or one of its
Subsidiaries free and clear of all liens or (b)&nbsp;licensed to the Company or one of its Subsidiaries.
Except as would not, individually or in the aggregate, have a Company Material Adverse Effect, (i)
the patent applications listed in <U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule that
are owned by the Company or any of its Subsidiaries are (and such applications that are licensed to
the Company or any of its Subsidiaries are to the Company&#146;s knowledge) pending and have not been
abandoned, and have been and continue to be timely prosecuted; (ii)&nbsp;all patents and applications
therefor, registered Trademarks and Trademark applications owned by the Company or any of its
Subsidiaries have been (and all such patents, patent applications, registered Trademarks and
applications licensed to the Company or any of its Subsidiaries have been to the Company&#146;s
knowledge) duly registered and/or filed with or issued by each appropriate Governmental Entity in
the jurisdiction indicated in <U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule, all
related necessary affidavits of continuing use, renewals and maintenance have been (or, with
respect to licenses, to the Company&#146;s knowledge have been) timely filed, and all related necessary
maintenance fees have been (or, with respect to licenses, to the Company&#146;s knowledge have been)
timely paid to continue all such rights in effect; (iii)&nbsp;none of the patents listed in <U>Section
4.13(d)</U> of the Company Disclosure Schedule that are owned by the Company or any of its
Subsidiaries has (and no such patents that are licensed to the Company or any of its Subsidiaries
has to the Company&#146;s knowledge) expired or been declared invalid, in whole or in part, by any
Governmental Entity; (iv)&nbsp;the registered Trademarks and Trademark applications listed in
<U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule that are owned by the Company or any of
its Subsidiaries are (and the registered Trademarks and Trademark applications that are licensed to
the Company or any of its Subsidiaries are to the Company&#146;s knowledge) valid, enforceable and in
full force and effect and have not lapsed, been abandoned or forfeited in whole or in part; and (v)
none of the Trademarks, Trademark registration or Trademark applications listed in <U>Section
4.13(d)</U> of the Company Disclosure Schedule that are owned by the Company or any of its
Subsidiaries is (and no such Trademarks, Trademark registration or Trademark applications that are
licensed to the Company or any of its Subsidiaries are to the knowledge of the Company) involved in
or the subject of any ongoing oppositions, cancellations or other proceedings. None of the patents
or patent applications listed in <U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule that
are owned by the Company or any of its Subsidiaries is (and no such patents or patent applications
that are licensed to the Company or any of its Subsidiaries are to the knowledge of the Company)
involved in or the subject of any ongoing interferences, oppositions, reissues or reexaminations in
the United States Patent and Trademark Office or in any foreign patent office or similar
administrative agency. To the knowledge of the Company, there are no published patents, patent
applications, articles or other prior art references that could adversely affect the validity of
any patent listed in <U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule in a material way.
Except as would not, individually or in the aggregate, have a Company Material Adverse Effect,
each of the patents and patent applications listed in <U>Section&nbsp;4.13(d)</U> of the Company
Disclosure Schedule that are owned by the Company or any of its Subsidiaries properly identifies
(and to the knowledge of the Company such patents and applications licensed
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">to the Company or any
of its Subsidiaries properly identify) each and every inventor of the claims thereof as determined
in accordance with the Laws of the jurisdiction in which such patent is issued or such patent
application is pending. Each inventor named on the patents and patent applications listed in
<U>Section&nbsp;4.13(d)</U> of the Company Disclosure Schedule that are owned by the Company or any of
its Subsidiaries has executed (and, to the knowledge of the Company, such inventors named on such
patents and applications that are licensed to and material to the Company and its Subsidiaries have
executed) an agreement assigning his, her or its entire right, title and interest in and to such
patent or patent application, and the inventions embodied and claimed therein, to the Company or a
Subsidiary of the Company, or, to the knowledge of the Company, in the case of licensed Patents, to
the appropriate owners. To the knowledge of the Company, no such inventor has any contractual or
other obligation that would preclude any such assignment or otherwise conflict with the obligations
of such inventor to the Company or such Subsidiary under such agreement with the Company or such
Subsidiary.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, all obligations for payment of monies currently due and payable by the Company or any of
its Subsidiaries have been satisfied in a timely manner in connection with options, rights,
licenses or interests of any kind relating to Intellectual Property Rights granted (i)&nbsp;to the
Company or any of its Subsidiaries (other than software licenses for generally available software
and except pursuant to employee proprietary inventions agreements (or similar employee agreements),
non-disclosure agreements and consulting agreements entered into by the Company or any of its
Subsidiaries in the ordinary course of business), or (ii)&nbsp;by the Company or any of its Subsidiaries
to any other person (including any obligations of such other person to make any fixed or contingent
payments, including royalty payments).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Company and its Affiliates have used reasonable efforts to maintain their trade
secrets in confidence, including the development of a policy for the protection of intellectual
property and periodic training for all employees of the Company and its Subsidiaries on the
implementation of such policy; requiring all employees of the Company and its Subsidiaries to
execute confidentiality agreements with respect to intellectual property developed for or obtained
from the Company or any of its Subsidiaries; making reasonable efforts to advise employees of the
Company and its Subsidiaries that were voluntarily or involuntarily severed from the Company or any
of its Subsidiaries of their continuing obligation to maintain such trade secrets in confidence;
and entering into licenses and contracts that generally require licensees, contractors and other
third persons with access to such trade secrets to keep such trade secrets confidential (which
licenses and contracts will be enforceable to the extent sufficient to fully exploit all such trade
secrets).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, the execution and delivery of this Agreement by the Company do not, and the consummation by
the Company of the transactions
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contemplated by this Agreement and compliance by the Company with
the provisions of this Agreement will not, conflict with, or result in any violation or breach of,
or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or
result in, termination, cancellation or acceleration of any obligation or to the loss of a benefit
under, or result in the creation of any lien in or upon, any Intellectual Property Right.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Except as would not, individually or in the aggregate, have a Company Material Adverse
Effect, (i)&nbsp;the Company and its Subsidiaries are not in violation of any condition or requirement
stipulated by the instruments of approval granted to the Company or its Subsidiaries by the OCS and
any applicable Laws and regulations with respect to any research and development grants given to
any of them by the OCS; and (ii)&nbsp;all information supplied by the Company and its Subsidiaries with
respect to such applications was true, correct and complete in all material respects when supplied
to the appropriate authorities. <U>Section&nbsp;4.13(h)</U> of the Company Disclosure Schedule sets
forth a complete and accurate list as of the date hereof of all the Company&#146;s or any of its
Subsidiaries&#146; Intellectual Property Rights that are subject to any restriction (including any
obligation for payment of royalties) under the Encouragement of Industrial Research and Development
Law, 5744-1984 and the regulations and instruments of approval promulgated thereunder by the OCS,
including the nature of such restriction and the amounts payable under said restriction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;None of Romata Holding AG, a corporation organized under the laws of Switzerland, or any
of its Affiliates owns or otherwise holds any rights in any Intellectual Property Rights necessary
for the conduct of the business of the Company and its Subsidiaries as currently conducted, and any
such Intellectual Property Rights previously owned by Romata Holdings AG or any of its Affiliates
have otherwise been validly transferred to the Company and/or its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.14 <U>Environmental</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company and its Subsidiaries are in compliance with all Environmental Laws, permits
and other governmental authorizations required for their current operations under applicable
Environmental Laws, except for noncompliance that would not, individually or in the aggregate, have
a Company Material Adverse Effect, and except as would not, individually or in the aggregate, have
a Company Material Adverse Effect, all such licenses, permits and authorizations are valid and in
good standing;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Neither the Company nor any of its Subsidiaries has received written notice alleging that
the Company or any of its Subsidiaries is in violation of, or has liability under, any
Environmental Law or any written request for information pursuant to any Environmental Law, and
there are no Environmental Claims pending or, to the knowledge of the Company, threatened against
the Company or any of its
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Subsidiaries except for such notices, requests or Environmental Claims
that would not, individually or in the aggregate, have a Company Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There has been no Release of, or exposure to, Hazardous Materials that require a Cleanup
by the Company or any of its Subsidiaries, or could otherwise be reasonably expected to form the
basis of any Environmental Claim against the Company or any of its Subsidiaries or against any
Person whose liabilities for such Environmental Claims the Company or any of its Subsidiaries has,
or may have, retained or assumed, either contractually or by operation of Law, other than any such
Cleanups or Environmental Claims that would not, individually or in the aggregate, have a Company
Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.15 <U>Labor Matters</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As of the date hereof, there are no pending or, to the knowledge of the Company or any of
its Subsidiaries, threatened strikes, lockouts, work stoppages or slowdowns involving the
Employees. As of the date hereof, neither the Company nor any of its Subsidiaries is a party to,
or bound by, any collective bargaining agreement, contract or other agreement or understanding with
a labor union or labor organization. To the knowledge of the Company or any of its Subsidiaries,
as of the date hereof, no labor union has made a demand for recognition or certification presently
pending with the National Labor Relations Board to represent any group of Employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As of the date hereof, there is no unfair labor practice charge or labor arbitration
proceeding pending or, to the knowledge of the Company or any of its Subsidiaries, threatened
against the Company or any of its Subsidiaries, except for any such charge or proceeding that would
not, individually or in the aggregate, result in a material liability to the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Each of the Company and its Subsidiaries is in compliance with all applicable Laws
respecting employment and employment practices, including all Laws respecting terms and conditions
of employment, wages, overtime classifications, classification of employees, consultants and
independent contractors, employment discrimination, equal opportunity and labor relations, except
for noncompliance that would not, individually or in the aggregate, result in a material liability
to the Company. There are no pending, or threatened in writing (or, to the knowledge of the
Company, other than in writing), charges against the Company or any Participant before any
Governmental Entity responsible for the prevention of unlawful employment practices. The
Company has not received notice (written or otherwise) of the intent of any Governmental Entity
responsible for the enforcement of labor or employment Laws to conduct an investigation of the
Company and, to the knowledge of the Company, no such investigation is in progress.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company and its Subsidiaries do not have and are not subject to, and no Participant
benefits from, any extension order (tzavei harchava) or any contract or arrangement with respect to
employment or termination thereof, other than such extension orders applicable to all employees in
Israel or to all employees in the industry field and pharmaceutical field specified by <U>Section
4.15(d)</U> of the Company Disclosure Schedule.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Section&nbsp;4.15(e)(i)</U> of the Company Disclosure Schedule contains a true and complete
list of the names, positions and rates of compensation of all officers, directors, employees and
consultants of the Company or of any of its Subsidiaries, as of the date hereof, showing each such
person&#146;s name, the employing entity, period of employment (or first date of employment), current
positions, and annualized base salaries, bonuses and fringe benefits for the current fiscal year.
All employees are employed on an &#147;at-will&#148; basis and their employment can be terminated at any time
(subject to the termination notice provisions included in employment agreements, which is not
longer than 30&nbsp;days, or the period prescribed by applicable Law) for any reason without any amounts
being owed to such individual other than with respect to wages accrued before the termination and
except for payments due under Israeli Law. The Company&#146;s relationships with all individuals who
act on their own as contractors or service providers to the Company can be terminated at any time
(subject to the termination notice provisions included in any such agreements, which is not longer
than 60&nbsp;days, or the period prescribed by applicable Law) for any reason without any amounts being
owed to such individual other than with respect to compensation or payments accrued before the
termination. No employee is on disability or other leave of absence. The Company has not
sponsored any employee for, or otherwise engaged any current employee working pursuant to, a
non-immigrant visa.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;As of the date of the most recent financial statements of the Company included in the
Filed SEC Reports, any and all obligations of the Company and its Subsidiaries to provide statutory
severance pay to its employees pursuant to the Israeli Severance Pay Law, 5723-1963 are fully
funded or accrued on the most recent financial statements of the Company included in the Company
SEC Reports and the Company&#146;s Subsidiaries incorporated in Israel use the provisions of Section&nbsp;14
of the Israeli Severance Pay Law with respect to such statutory severance pay with respect to all
of their employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;As of the date hereof, (i)&nbsp;the Company has not been notified in writing by any of the
Specified Participants that such Specified Participant intends to,
or is considering, terminating such Specified Participant&#146;s employment with or service to the
Company, including in connection with or as a result, in part or in whole, of the transactions
contemplated hereby or any other sale of the Company, and (ii)&nbsp;to the knowledge of the Company, no
Specified Participant intends to and no Specified Participant has notified the Company (or any
Person included in the definition of knowledge) that such employee is considering doing the same.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;To the knowledge of the Company, no employee or director of the Company is a party to or
bound by any license, covenant or contract of any nature, or subject to any judgment of any
Governmental Entity, that substantially limits such Person&#146;s ability to be employed by or provide
services to the Company. To the knowledge of the Company (i)&nbsp;no activity of any Specified
Participant as or while a Specified Participant has caused a violation of any employment contract,
confidentiality agreement, patent disclosure agreement, or other contract, and (ii)&nbsp;neither the
execution and delivery of this Agreement nor the conduct of the business of the Company by the
Specified Participants, will conflict with or result in a breach of the terms, conditions or
provisions of, or constitute a default (with or without notice or lapse of time or both) under, or
give rise to a right of, or result in, termination, cancellation or acceleration of any obligation
or to a loss of a material benefit under, or give rise to any increased, additional, accelerated or
guaranteed rights or entitlements under any covenant or instrument under which any such Specified
Participants are now obligated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;All current Participants other than consultants have executed and delivered to the Company
or one of its Subsidiaries a confidential information, non-solicitation and non-competition
agreement which agreement covers all periods that a Participant has been employed by the Company or
one of its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.16 <U>Offer Documents; Proxy Statement</U>. None of the information supplied by the Company for inclusion in (or incorporated by reference
in) (i)&nbsp;the Offer Documents and the Schedule&nbsp;14D-9 will, on the date each such document is filed
with the SEC or on the date each such document is first published, sent or given to stockholders of
the Company, contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, and (ii)&nbsp;the Proxy Statement (if required
by applicable Law) will, on the date the Proxy Statement is first mailed to stockholders of the
Company or at the time of the Company Special Meeting, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading,
except, in each case, that no representation or warranty is made by the Company with respect to
statements made or incorporated by reference therein based on information supplied by or on behalf
of Parent or Sub for inclusion or incorporation by reference therein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.17 <U>Takeover Laws</U>. The Company has taken all action necessary to exempt the Offer, the Merger, this Agreement and
the transactions contemplated hereby from the provisions of Section&nbsp;203 of the DGCL, and such
action is effective as of the date hereof. To the knowledge of the Company, no other state
takeover statute or other similar Law applies to the Offer, the Merger, this Agreement or the other
transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.18 <U>Contracts</U>.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except with respect to licenses and other agreements relating to intellectual property,
which are the subject of <U>Section&nbsp;4.13</U>, as of the date hereof, neither the Company nor any
of its Subsidiaries is a party to, and none of their respective properties or other assets is
subject to, any agreement that is of a nature required to be filed as an exhibit to a report or
filing under the Securities Act or the Exchange Act and the rules and regulations promulgated
thereunder. Neither the Company nor any of its Subsidiaries is a party to or otherwise bound by
any agreement or covenant (A)&nbsp;restricting in any material respect the Company&#146;s or its
Subsidiaries&#146; ability to compete, (B)&nbsp;restricting in any respect the Company&#146;s Affiliates&#146; ability
to compete (other than the Company&#146;s Subsidiaries), (C)&nbsp;restricting in any material respect the
research, development, distribution, sale, supply, license, marketing or manufacturing of products
or services of the Company or any of its Subsidiaries, (D)&nbsp;restricting in any respect the research,
development, distribution, sale, supply, license, marketing or manufacturing of products or
services of any of the Company&#146;s Affiliates (other than the Company&#146;s Subsidiaries), (E)&nbsp;containing
a right of first refusal, right of first negotiation or right of first offer in favor of a party
other than the Company or its Subsidiaries, (F)&nbsp;requiring the Company or its Subsidiaries to
license any fields of use for any of their products or (G)&nbsp;requiring the Company or its
Subsidiaries to give distribution rights to its products to any third party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Section&nbsp;4.18(b)(i)</U> of the Company Disclosure Schedule sets forth, as of the date
hereof, a complete and accurate list of all contracts to which the Company or any of its
Subsidiaries is a party as of the date hereof relating to (x)&nbsp;the distribution, sale, supply or
license of products of the Company or any of its Subsidiaries or (y)&nbsp;construction or capital
equipment. <U>Section&nbsp;4.18(b)(ii)</U> of the Company Disclosure Schedule sets forth, as of the
date hereof, a complete and accurate list of all contracts with a value (or involving amounts) in
excess of $1,000,000 to which the Company or any of its Subsidiaries is a party as of the date
hereof relating to (x)&nbsp;leases of any nature or (y)&nbsp;research, clinical trial, development,
marketing, co-promotion or manufacturing of (1)&nbsp;products (including products under development) of
the Company or any of its Subsidiaries, (2)&nbsp;products (including products under development)
licensed by the Company or any of its Subsidiaries or (3)&nbsp;the Intellectual Property Rights of the
Company or any of its Subsidiaries (all such contracts required to be set forth on <U>Section </U>
<U>4.18(b)(i)</U> and <U>(b)(ii)</U> of the Company Disclosure Schedule, collectively, the
&#147;<U>Specified Contracts</U>&#148;). No contract to which the Company or any of its Subsidiaries is a
party (A)&nbsp;grants or obligates the Company or any of its Subsidiaries to grant an exclusive right
(or, in the case of any product that has not been approved for commercial sale, any right) to such
third party for the research, clinical trial, development, distribution, sale, supply, license,
marketing, co-promotion or manufacturing of any product or Intellectual Property Right, (B)
provides for the payment by the Company or any of its Subsidiaries of any early termination fees or
(C)&nbsp;requires or obligates the Company or any of its Subsidiaries to purchase specified minimum
amounts of any product or to perform or conduct research, clinical trials or development for the
benefit of any person other than the Company or any of its Subsidiaries.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Section&nbsp;4.18(c)</U> of the Company Disclosure Schedule sets forth, as of the date
hereof, a complete and accurate list of all contracts that are currently in effect between or among
the Company or any of its Subsidiaries, on the one hand, and any current or former Participant (or
Affiliate of a current or former Participant), on the other hand.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;None of the Company, any of its Subsidiaries or, to the knowledge of the Company, any
other party thereto is in violation of or in default under (nor does there exist any condition
which upon the passage of time or the giving of notice or both would cause such a violation of or
default under) (A)&nbsp;any agreement or covenant described in <U>Section&nbsp;4.18(a)</U> or any Specified
Contract to which it is a party or by which it or any of its properties or other assets is bound,
except for violations or defaults that, individually or in the aggregate, would not result in a
material liability to the Company or any of its Subsidiaries or (B)&nbsp;any real property lease or
sublease to which it is a party or by which it or any of its properties or other assets is bound,
except for violations or defaults that, individually or in the aggregate, would not have a Company
Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.19 <U>Voting Requirements</U>. Assuming the accuracy of the representation given by Parent and Sub in <U>Section&nbsp;5.7</U>, the
affirmative vote (in person or by proxy) of the holders of a majority of the outstanding Shares at
the Company Special Meeting, or any adjournment or postponement of the Company Special Meeting, in
favor of the adoption of this Agreement is the only vote (if any vote is required by Law), of the
holders of any class or series of capital stock of the Company necessary to adopt this Agreement
and approve the transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.20 <U>Brokers or Finders</U>. No investment banker, broker, finder, consultant or intermediary other than UBS Securities LLC,
the fees and expenses of which will be paid by the Company, is entitled to any investment banking,
brokerage, finder&#146;s or similar fee or commission in connection with this Agreement or the
transactions contemplated hereby based upon arrangements
made by or on behalf of the Company or any of its Subsidiaries. The Company has delivered to
Parent complete and accurate copies of all contracts under which any such fees or expenses are
payable and all indemnification and other agreements related to the engagement of the Persons to
whom such fees are payable. The fees and expenses of all accountants, brokers, financial advisors
(including UBS Securities LLC), legal counsel (including Skadden, Arps, Slate, Meagher &#038; Flom LLP)
and other Persons retained by the Company or any of its Subsidiaries incurred or to be incurred by
the Company or any of its Subsidiaries in connection with this Agreement or the transactions
contemplated hereby will not exceed the amount set forth in <U>Section&nbsp;4.20</U> of the Company
Disclosure Schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.21 <U>Opinion of Financial Advisor</U>. The Board of Directors of the Company has received the opinion of UBS Securities LLC to the
effect that, as of the date of such opinion and based upon and subject to the matters set forth in
such opinion, the consideration to be received by the holders of Shares (other than Parent, Sub and
their
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">respective affiliates) pursuant to the Offer and the Merger, taken together, is fair, from a
financial point of view, to such holders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.22 <U>Relationships with Customers and Suppliers</U>. Between December&nbsp;31, 2007 and the date hereof, no customer or supplier of the Company or any of
its Subsidiaries that is material to the Company and its Subsidiaries has canceled or otherwise
terminated, or provided written notice to the Company or any of its Subsidiaries of its intent, or,
to the knowledge of the Company, threatened, to terminate its relationship with the Company or its
applicable Subsidiary, or, between December&nbsp;31, 2007 and the date hereof, decreased or limited in
any material respect, or provided written notice to the Company or any of its Subsidiaries of its
intent, or, to the knowledge of the Company, threatened in writing, to decrease or limit in any
material respect, its purchases from or sales to the Company or any of its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.23 <U>No Other Representations</U>. Except for the representations and warranties contained in this <U>ARTICLE IV</U>, neither the
Company nor any other Person acting on behalf of the Company, makes any representation or warranty,
express or implied.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>REPRESENTATIONS AND WARRANTIES </B></U><BR>
<U><B>OF PARENT AND SUB</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent and Sub jointly and severally represent and warrant to the Company as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.1 <U>Organization</U>. Each of Parent and Sub is a corporation, partnership or other entity duly organized, validly
existing and (to the extent applicable) in good standing under the laws of the jurisdiction of its
incorporation or organization and has the requisite entity power and authority to own, lease and
operate its properties and to carry on its business as it is now being conducted, except where the
failure to be so existing and in good standing or to have such power and authority would not,
individually or in the aggregate, have a Parent Material Adverse Effect. Each of Parent and Sub is
duly qualified or licensed to do business and is in good standing in each jurisdiction in which the
property owned, leased or operated by it or the nature of the business conducted by it makes such
qualification or licensing necessary, except where the failure to be so duly qualified, licensed
and in good standing would not, individually or in the aggregate, have a Parent Material Adverse
Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.2 <U>Authorization; Validity of Agreement; Necessary Action</U>. Each of Parent and Sub has all necessary corporate power and authority to execute and deliver
this Agreement, to perform their respective obligations hereunder and to consummate the
transactions contemplated by this Agreement. The execution, delivery and performance by Parent and
Sub of this Agreement, and the consummation by Parent and Sub of the transactions contemplated by
this Agreement, have been duly authorized
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and approved by their respective Boards of Directors and
will be adopted by Parent as the sole stockholder of Sub, and no other corporate action on the part
of Parent and Sub is necessary to authorize the execution, delivery and performance by Parent and
Sub of this Agreement and the consummation by them of the transactions contemplated by this
Agreement. This Agreement has been duly executed and delivered by Parent and Sub and (assuming due
and valid authorization, execution and delivery hereof by the Company) is a valid and binding
obligation of each of Parent and Sub, enforceable against each of them in accordance with its
terms, except that (i)&nbsp;such enforcement may be subject to applicable bankruptcy, insolvency,
reorganization, moratorium or other similar Laws, now or hereafter in effect, affecting creditors&#146;
rights and remedies generally and (ii)&nbsp;the remedy of specific performance and injunctive and other
forms of equitable relief may be subject to equitable defenses and to the discretion of the court
before which any proceeding therefor may be brought.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.3 <U>Consents and Approvals; No Violations</U>. Except for (a)&nbsp;filings pursuant to the Israeli Anti-Trust Law or any other required antitrust
filings and the receipt, termination or expiration, as applicable, of approvals or waiting periods
required under any applicable competition, merger control, antitrust or similar Law, (b)&nbsp;filings of
customary applications and notices, as applicable, with the FDA, the EMEA or any other federal,
state, local or foreign Regulatory Authority, (c)&nbsp;applicable requirements of and filings with the
SEC under the Exchange Act, (d)&nbsp;filings with the New York Stock Exchange, (e)&nbsp;the filing of the
Certificate of Merger and (f)&nbsp;applicable requirements under corporation or &#147;blue sky&#148; laws of
various states, neither the execution, delivery or performance of this Agreement by Parent and Sub
nor the consummation by Parent and Sub of the transactions contemplated hereby will (i)&nbsp;violate any
provision of the certificate of incorporation or bylaws (or equivalent organizational
document) of Parent or Sub, (ii)&nbsp;result in a violation or breach of, or constitute (with or without
due notice or lapse of time or both) a default (or give rise to any right of termination,
cancellation or acceleration) under, any of the terms, conditions or provisions of any note, bond,
mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which
Parent or any of its Subsidiaries is a party or by which any of them or any of their properties or
assets may be bound, (iii)&nbsp;violate any Law applicable to Parent, any of its Subsidiaries or any of
their properties or assets or (iv)&nbsp;require on the part of Parent or Sub any material filing or
registration with, notification to, or authorization, consent or approval of, any Governmental
Entity; except in the case of clauses (ii)&nbsp;and (iii)&nbsp;for such violations, breaches, defaults,
terminations, cancellations or accelerations that would not, individually or in the aggregate, have
a Parent Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.4 <U>Sub&#146;s Operations</U>. Sub was formed solely for the purpose of engaging in the transactions contemplated hereby and
has not owned any assets, engaged in any business activities or conducted any operations other than
in connection with the transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.5 <U>Information Supplied</U>. None of the information supplied by Parent or Sub for inclusion in (or incorporated by reference
in) (i)&nbsp;the Offer Documents and the Schedule&nbsp;14D-9 will, on the date each such document is filed
with the SEC or on
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the date each such document is first published, sent or given to stockholders of
the Company, contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, and (ii)&nbsp;the Proxy Statement (if required
by applicable Law) will, on the date the Proxy Statement is first mailed to stockholders of the
Company or at the time of the Company Special Meeting, contain any untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading,
except, in each case, that no representation or warranty is made by Parent or Sub with respect to
statements made or incorporated by reference therein based on information supplied by or on behalf
of the Company for inclusion or incorporation by reference therein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.6 <U>Sufficient Funds</U>. Parent has, and as of the Closing shall have, sufficient funds available (through existing
credit arrangements or otherwise) to fully fund all of Parent&#146;s and Sub&#146;s obligations under this
Agreement, including payment of the aggregate Offer Price, the aggregate Merger Consideration, the
Option Consideration and payment of all fees and expenses related to the transactions contemplated
by this Agreement and any refinancing of indebtedness of Parent or the Company or their respective
Subsidiaries in connection therewith.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.7 <U>Share Ownership</U>. Neither Parent nor Sub has been, at any time during the three years preceding the date hereof,
an &#147;interested stockholder&#148; of the Company, as defined in Section&nbsp;203 of the DGCL.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.8 <U>Investigation by Parent and Sub</U>. Each of Parent and Sub has conducted its own independent review and analysis of the businesses,
assets, condition, operations and prospects of the Company and its Subsidiaries and acknowledges
that each of Parent and Sub has been provided access to the properties, premises and records of the
Company and its Subsidiaries for this purpose. In entering into this Agreement, each of Parent and
Sub has relied solely upon its own investigation and analysis, and each of Parent and Sub
acknowledges that, except for the representations and warranties of the Company expressly set forth
in <U>ARTICLE IV</U>, none of the Company or its Subsidiaries nor any of their respective
Representatives makes any representation or warranty, either express or implied, as to the accuracy
or completeness of any of the information provided or made available to Parent or Sub or any of
their Representatives. Without limiting the generality of the foregoing, none of the Company or
its Subsidiaries nor any of their respective Representatives or any other Person has made a
representation or warranty to Parent or Sub with respect to (a)&nbsp;any projections, estimates or
budgets for the Company or its Subsidiaries or (b)&nbsp;any material, documents or information relating
to the Company or its Subsidiaries made available to each of Parent or Sub or their Representatives
in any &#147;data room,&#148; confidential memorandum or otherwise, except as expressly and specifically
covered by a representation or warranty set forth in <U>ARTICLE IV</U>.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>COVENANTS</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.1 <U>Interim Operations of the Company</U>. From and after the date of this Agreement, except (w)&nbsp;as may be required by Law, (x)&nbsp;with the
prior written consent of Parent (which consent shall not be unreasonably withheld, delayed or
conditioned), (y)&nbsp;as expressly contemplated or permitted by this Agreement or (z)&nbsp;as set forth in
the <U>Section&nbsp;6.1</U> of the Company Disclosure Schedule, the business of the Company and its
Subsidiaries shall be conducted only in the ordinary and usual course of business consistent with
past practice, and, to the extent consistent therewith, the Company shall, and shall cause its
Subsidiaries to, use reasonable efforts to (i)&nbsp;preserve intact their current business organization
and (ii)&nbsp;preserve their present relationships with customers, suppliers and others having business
dealings with them who are integral to the operation of their businesses as presently conducted;
<U>provided</U>, <U>however</U>, that no action by the Company with respect to matters addressed
specifically by any provision of this <U>Section&nbsp;6.1</U> shall be deemed a breach of this sentence
unless such action would constitute a breach of such specific provision. Without limiting the
generality of the foregoing, except (A)&nbsp;as may be required by Law, (B)&nbsp;with the prior written
consent of Parent (which consent shall not be unreasonably withheld, delayed or
conditioned), (C)&nbsp;as expressly contemplated or permitted by this Agreement or (D)&nbsp;as set forth in
<U>Section&nbsp;6.1</U> of the Company Disclosure Schedule, from and after the date of this Agreement,
neither the Company nor its Subsidiaries will:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;except for Shares to be issued or delivered pursuant to the exercise of Company Options or
Warrants outstanding on the date hereof or the issuance of the shares of capital stock of any
Subsidiary to the Company, issue, deliver, sell, dispose of, pledge or otherwise encumber, or
authorize or propose the issuance, delivery, sale, disposition or pledge or other encumbrance of
(i)&nbsp;any shares of its capital stock of any class or any other ownership interest, or any securities
or rights convertible into, exchangeable for, or evidencing the right to subscribe for any shares
of its capital stock or any other ownership interest, or any rights, warrants, options, calls,
commitments or any other agreements of any character to purchase or acquire any shares of its
capital stock or any other ownership interest or any securities or rights convertible into,
exchangeable for, or evidencing the right to subscribe for, any shares of its capital stock or any
other ownership interest (including &#147;phantom&#148; rights and stock appreciation rights), or (ii)&nbsp;any
other securities of the Company and its Subsidiaries in respect of, in lieu of, or in substitution
for, Shares outstanding on the date hereof;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;redeem, purchase or otherwise acquire, or propose to redeem, purchase or otherwise
acquire, any outstanding Shares, Company Options, Warrants or other securities of the Company or
any of its Subsidiaries; <U>provided</U>, <U>however</U>, that the Company may (i)&nbsp;withhold
Shares to satisfy Tax obligations with respect to Company Options, Restricted Stock Awards and
Company RSUs granted prior to the date hereof pursuant to the Equity Plans and (ii)&nbsp;acquire Shares
in connection with the surrender of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Shares by holders of Company Options or Warrants in order to
pay the exercise price of the Company Options or Warrants;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;split, combine, subdivide or reclassify any Shares or declare, set aside for payment or
pay any dividend in respect of any Shares or otherwise make any payments or distributions to
stockholders of the Company or of any Subsidiary of the Company that is not wholly owned (directly
or indirectly) by Company in their capacity as such;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;adopt a plan of complete or partial liquidation, dissolution, merger, consolidation,
restructuring, recapitalization or other reorganization of the Company or any of its Subsidiaries,
other than the Merger;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;acquire (x)&nbsp;by purchase, merger or otherwise, any business or equity interest of any
Person or (y)&nbsp;any asset or assets that, individually, has a purchase price in excess of $100,000
or, in the aggregate, have a purchase price in excess of $250,000, except for purchases of
components, raw materials or supplies in the ordinary course of business consistent with past
practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;sell, lease, license, mortgage, sell and leaseback or otherwise encumber or dispose of any
of its properties or other assets or any interests therein, except for sales of inventory and used
equipment in the ordinary course of business consistent with past practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;incur any indebtedness for borrowed money in addition to that incurred as of the date of
this Agreement or guarantee any such indebtedness or make any loans, advances or capital
contributions to, or investments in, any other Person, other than to the Company and its wholly
owned Subsidiaries, and other than to employees in respect of travel or other related expenses in
the ordinary course of business consistent with past practice;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;except as may be contemplated by <U>Section&nbsp;6.5(c)</U> of this Agreement, except as
required by Law or except as required by a Benefit Plan in accordance with its terms as of the date
of this Agreement, (i)&nbsp;grant to any Participant any right to severance, retention, change in
control or termination compensation or benefits, or increase any Participant&#146;s rights thereto, (ii)
grant any Participant any increase in compensation, bonus, fringe or other benefits (except that,
if the Closing shall not have occurred prior to February&nbsp;1, 2009, the Company may make normal
increases in cash compensation for employees and consultants who are not Specified Participants),
(iii)&nbsp;pay or provide any compensation or benefit to any Participant that is not required under a
Benefit Plan (other than the payment of normal cash wages or salaries in the ordinary
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">course of
business consistent with past practice) or (iv)&nbsp;enter into, adopt, amend or terminate any
collective bargaining agreement or Benefit Plan;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;except as required by any Benefit Plan in accordance with its terms as of the date of this
Agreement, take any action to fund or in any other way secure the payment of compensation and
benefits under any Benefit Plan, take any action to accelerate the vesting or payment of any
compensation or benefits under any Benefit Plan or materially change any assumption used to
calculate funding obligations with respect to any Benefit Plan or change the manner in which
contributions to any Benefit Plan are made or the basis on which such contributions are determined;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;change any of the accounting methods used by the Company or its Subsidiaries unless
required by GAAP or applicable Law;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;amend the Company&#146;s certificate of incorporation or the Company&#146;s bylaws or other
comparable charter or organizational documents of any of the Company&#146;s Subsidiaries, except as may
be required by applicable Law and except for immaterial amendments under the charter or
organizational documents of any Subsidiary of the Company;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;make any new capital expenditure or other expenditures (including in respect of research
and development), other than those which, individually, are less than or equal to $100,000 or, in
the aggregate, are less than or equal to $250,000;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;except as required by applicable Law, (i)&nbsp;pay, discharge, settle or satisfy any claims,
liabilities, obligations or litigation (absolute, accrued, asserted or unasserted, contingent or
otherwise), other than the payment, discharge, settlement or satisfaction in the ordinary course of
business consistent with past practice or in accordance with their terms, of liabilities reserved
against in the most recent financial statements of the Company included in the Filed SEC Reports
(for amounts not in excess of such reserves) or incurred since the date of such financial
statements in the ordinary course of business consistent with past practice, (ii)&nbsp;cancel any
indebtedness, (iii)&nbsp;waive or assign any claims or rights of substantial value, (iv)&nbsp;waive any
benefits of, or agree to modify in any respect, or, subject to the terms hereof, fail to enforce,
or consent to any matter with respect to which consent is required under, any standstill or similar
contract to which the Company or any of its Subsidiaries is a party or (v)&nbsp;waive any material
benefits of, or agree to modify in any material respect, or, subject to the terms hereof, fail to
enforce in any material respect, or consent to any matter with respect to which consent is required
under, any material confidentiality or similar contract to which the Company or any of its
Subsidiaries is a party;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;other than in the ordinary course of business consistent with past practice, (i)&nbsp;enter
into any contracts relating to research, clinical trial, development, sale, supply, marketing or
manufacturing by third parties of products (including products under development) of the Company or
any of its Subsidiaries or products (including products under development) licensed by the Company
or any of its Subsidiaries, (ii)&nbsp;initiate, launch or commence any sale, marketing, distribution,
co-promotion or any similar activity with respect to any new product (including products under
development) or (iii)&nbsp;file any new application for OCS grants or agree to accept any OCS grants
deriving from an existing OCS program or file any amendment or agree to amend the terms of any
existing OCS program;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;enter into, modify, amend or terminate any contract or waive, release, assign or fail to
exercise or pursue any material rights or claims thereunder, which if so entered into, modified,
amended, terminated, waived, released, assigned, or not exercised or pursued would reasonably be
expected to (i)&nbsp;adversely affect the Company and its Subsidiaries in any material respect,
(ii)&nbsp;impair in any material respect the ability of the Company to perform its obligations under
this Agreement or (iii)&nbsp;prevent or materially delay the consummation of the transactions
contemplated by this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;(i)&nbsp;make or change any material Tax election, (ii)&nbsp;change any Tax accounting period or
method, (iii)&nbsp;file any amended Tax Return, (iv)&nbsp;enter into any closing agreement with respect to
Taxes, (v)&nbsp;settle any Tax claim or assessment, (vi)
surrender any right to claim a material refund of Taxes, (vii)&nbsp;consent to any extension or
waiver of the limitations period for the assessment of Taxes, (viii)&nbsp;file any new application for
an &#147;Approved Enterprise&#148; status or file any amendment or agree to amend the terms of any existing
&#147;Approved Enterprise&#148; status, (ix)&nbsp;make or change any Tax election to treat the Company or any of
its Subsidiaries as other than a corporation as defined in Treasury Regulations 301.7701-2 and
301.7701-3 (or any similar definition in any applicable foreign Law), or (x)&nbsp; take any other action
outside the ordinary course of business if taking such action would materially affect the Tax of
either the Company or any of its Subsidiaries after the Closing Date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(q)&nbsp;sell, transfer or license to any person or adversely amend or modify any rights (i)&nbsp;to any
Company Intellectual Property Rights or (ii)&nbsp;to distribute, license or co-promote any product of
the Company or any of its Subsidiaries (including products under development and products licensed
by the Company or any of its Subsidiaries); or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(r)&nbsp;enter into any contract, agreement, commitment or arrangement to do any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.2 <U>Advice of Changes; Filings</U>. The Company and Parent shall promptly advise the other party orally and in writing of (i)&nbsp;any
representation or
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">warranty made by it (and, in the case of Parent, made by Sub) contained in this
Agreement becoming untrue or (ii)&nbsp;the failure of it (and, in the case of Parent, of Sub) to comply
with or satisfy in any material respect any covenant, condition or agreement to be complied with or
satisfied by it (and, in the case of Parent, of Sub) under this Agreement; <U>provided</U>,
<U>however</U>, that no such notification shall affect the representations, warranties, covenants
or agreements of the parties (or remedies with respect thereto) or the conditions to the
obligations of the parties under this Agreement. The Company and Parent shall, to the extent
permitted by Law, promptly provide the other with copies of all filings made by such party (and, in
the case of Parent, by Sub) with any Governmental Entity in connection with this Agreement and the
transactions contemplated hereby, other than the portions of such filings that include confidential
information not directly related to the transactions contemplated by this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.3 <U>Access to Information</U>. The Company shall afford to officers, employees, counsel, investment bankers, accountants and
other authorized representatives (the foregoing, with respect to any Person, its
&#147;<U>Representatives</U>&#148;) of Parent reasonable access, in a manner not disruptive to the
operations of the business of the Company and its Subsidiaries, during normal business hours and
upon reasonable notice throughout the period prior to the Effective Time, to the properties,
personnel, books and records of the Company and its Subsidiaries and, during such period, shall
furnish promptly to Parent&#146;s Representatives all information concerning the business, properties
(including Phase I environmental assessments) and personnel of the Company and its Subsidiaries as
may reasonably be
requested; <U>provided</U>, <U>however</U>, that nothing herein shall require the Company to
disclose any information to Parent or Sub if such disclosure, in the reasonable judgment of the
Company, would (i)&nbsp;violate applicable Law or the provisions of any agreement to which the Company
is a party or (ii)&nbsp;jeopardize any attorney-client or other legal privilege. Parent agrees that it
will not, and will cause its Representatives not to, use any information obtained pursuant to this
<U>Section&nbsp;6.3</U> for any competitive or other purpose unrelated to the consummation of the
transactions contemplated by this Agreement; <U>provided further</U>, <U>however</U>, that
nothing herein shall authorize Parent or its Representatives to undertake any intrusive or
subsurface Phase II environmental assessments or sampling at any of the properties owned, operated
or leased by the Company or any of its Subsidiaries. The Nondisclosure Agreement shall apply with
respect to information furnished by the Company and the Company&#146;s officers, employees and other
Representatives hereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.4 <U>Acquisition Proposals</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;From the date of this Agreement until the Effective Time or, if earlier, the termination
of this Agreement in accordance with its terms, the Company will not, nor shall it authorize or
permit any of its Subsidiaries or any of its or their respective officers, directors, employees and
other Representatives to, (i)&nbsp;initiate, solicit or take any action to facilitate, directly or
indirectly, any inquiries regarding or the making of any Acquisition Proposal or (ii)&nbsp;except as
permitted below, engage in negotiations or discussions with, or furnish any information or data to,
any Person relating to an Acquisition Proposal.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Notwithstanding anything to the contrary in this Agreement, at any time prior to the
Acceptance Date, in the event that the Company receives an unsolicited written Acquisition Proposal
after the date hereof that did not result from a breach of this <U>Section&nbsp;6.4</U>, the Company
and its Board of Directors may participate in discussions or negotiations (including, as a part
thereof, making any counterproposal) with, or furnish any information and access to, any Person
making such Acquisition Proposal and its Representatives or potential sources of financing if (i)
the Company&#146;s Board of Directors determines in good faith, after consultation with the Company&#146;s
outside legal counsel and financial advisor, that such Person is reasonably likely to submit to the
Company an Acquisition Proposal that is a Superior Proposal and (ii)&nbsp;the Company&#146;s Board of
Directors determines in good faith, after consultation with its counsel, that the failure to
participate in such discussions or negotiations or to furnish such information would be
inconsistent with the directors&#146; fiduciary duties to the Company&#146;s stockholders under applicable
Law; <U>provided</U> that all such information so furnished has been previously provided to Parent
or is provided to Parent substantially concurrent with it being so furnished to such Person or its
Representatives. In addition, nothing herein shall restrict the Company from complying with its
disclosure obligations with regard to any Acquisition Proposal under applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Neither the Board of Directors of the Company nor any committee thereof shall (i) (A)
withdraw (or modify in a manner adverse to Parent or Sub), or publicly propose to withdraw (or so
modify) the recommendation by the Board of Directors of the Company and any committee thereof of
the Offer, the Merger or this Agreement or (B)&nbsp;recommend, adopt or approve, or propose publicly to
recommend, adopt or approve, any Acquisition Proposal (any action described in this clause (i)
being referred to as a &#147;<U>Change in Recommendation</U>&#148;) or&nbsp;(ii)&nbsp;approve or recommend, or propose
to approve or recommend, or allow the Company or any of its Affiliates to execute or enter into,
any letter of intent, memorandum of understanding, agreement in principle, merger agreement,
acquisition agreement, option agreement, joint venture agreement, partnership agreement or other
similar agreement constituting or related to, or that is intended to or would reasonably be
expected to lead to, any Acquisition Proposal (other than a customary confidentiality agreement)
(any such agreement, an &#147;<U>Acquisition Agreement</U>&#148;). Notwithstanding anything in this
Agreement to the contrary, at any time prior to the Acceptance Date, the Board of Directors of the
Company may (i)&nbsp;make a Change in Recommendation if the Board of Directors of the Company determines
in good faith (after consultation with its counsel and financial advisor) that the failure to take
such action would be inconsistent with the directors&#146; fiduciary duties to the stockholders of the
Company under applicable Law and (ii)&nbsp;terminate this Agreement to accept a Superior Proposal that
was not solicited after the date hereof and did not otherwise result from a breach of this
<U>Section&nbsp;6.4</U>;<SUP style="font-size: 85%; vertical-align: text-top"> </SUP><U>provided</U>, <U>however</U>, that (1)&nbsp;no Change in
Recommendation may be made and (2)&nbsp;no termination of this Agreement pursuant to this <U>Section
6.4(c)</U> may be made, in each case until after the fifth&nbsp;(5th) Business Day following Parent&#146;s
receipt of written notice from the Company advising Parent that the Board of Directors of the
Company intends to make a Change in Recommendation (a &#147;<U>Notice of Adverse Recommendation</U>&#148;)
or terminate this Agreement pursuant to this <U>Section&nbsp;6.4(c)</U> (a &#147;<U>Notice of Superior
Proposal</U>&#148;) and specifying the reasons therefor,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">including, if the basis of the proposed action
by the Company&#146;s Board of Directors is a Superior Proposal, the terms and conditions of any such
Superior Proposal (it being understood and agreed that any amendment to the financial terms or any
other material term of such Superior Proposal shall require a new Notice of Adverse Recommendation
or Notice of Superior Proposal and a new five&nbsp;(5) Business Day period). In determining whether to
make a Change in Recommendation, the Board of Directors of the Company shall take into account any
changes to the terms of this Agreement proposed by Parent in response to a Notice of Adverse
Recommendation, a Notice of Superior Proposal or otherwise.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Company shall promptly advise Parent orally and in writing of any Acquisition
Proposal, the material terms and conditions of any such Acquisition Proposal (including any changes
thereto) and the identity of the person making any such Acquisition Proposal. The Company shall
(i)&nbsp;keep Parent fully informed of the status and material details (including any change to the
terms thereof) of any such Acquisition Proposal and any discussions and negotiations concerning the
material terms and conditions thereof and (ii)&nbsp;provide to Parent as soon as practicable after
receipt or delivery thereof copies of all correspondence and other written material&nbsp;(including all
draft agreements and any comments thereon) relating to any such
Acquisition Proposal exchanged between the Company or any of its Subsidiaries&nbsp;(or their
Representatives), on the one hand, and the Person making an Acquisition Proposal (or its
Representatives), on the other hand.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.5 <U>Employee Benefits</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;For a period of one (1)&nbsp;year following the Effective Time, Parent shall, subject to any
requirements imposed by local Law, cause to be provided to employees of the Company and its
Subsidiaries who are primarily employed in the United States (the &#147;<U>US Employees</U>&#148;) who
remain in the employment of the Surviving Corporation base salary or hourly wage rates that, on an
individual-by-individual basis, are no less favorable than those provided to such US Employees
immediately prior to the Effective Time. Parent shall cause the Surviving Corporation to recognize
the service of each US Employee as if such service had been performed with Parent (i)&nbsp;for purposes
of vesting (but not benefit accrual) under Parent&#146;s defined benefit pension plan, (ii)&nbsp;for purposes
of vesting under Parent&#146;s 401(k) retirement plan, (iii)&nbsp;for purposes of eligibility for vacation
under Parent&#146;s vacation program, (iv)&nbsp;for purposes of eligibility and participation under any
health or welfare plan maintained by Parent (other than any post-employment health or
post-employment welfare plan) and (v)&nbsp;unless covered under another arrangement with or of the
Company, for benefit accrual purposes under Parent&#146;s severance plan (in the case of each of
clauses&nbsp;(i), (ii), (iii), (iv)&nbsp;and (v), solely to the extent that Parent makes such plan or program
available to such US Employee and not in any case where credit would result in duplication of
benefits), but not for purposes of any other employee benefit plan of Parent. Each benefit plan,
program, practice, policy or arrangement maintained by Parent or its Subsidiaries following the
Effective Time and in which US Employees participate (the &#147;<U>Parent Plans</U>&#148;) shall waive
pre-existing condition
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">limitations to the extent waived or not applicable under the applicable
Benefit Plan. US Employees shall be given credit under the applicable Parent Plan for amounts paid
prior to the Effective Time during the year in which the Effective Time occurs under a
corresponding Benefit Plan during the same period for purposes of applying deductibles, co-payments
and out-of-pocket maximums as though such amounts had been paid in accordance with the terms and
conditions of the Parent Plan. Parent shall cause to be provided to employees of the Company and
its Subsidiaries who are primarily employed in Israel (the &#147;<U>Israeli Employees</U>&#148; and,
together with the US Employees, the &#147;<U>Employees</U>&#148;) any terms and conditions of employment
(including plans, programs and social insurance contributions or arrangements) to the extent
required by Israeli Law in order for Parent, the Surviving Corporation and their Subsidiaries to
avoid any liability that would otherwise result from a failure to comply with relevant Israeli Law
and honor all Benefit Plans and Specified Benefit Agreements in which (or to which) such Israeli
Employees are a participant or a party in accordance with their terms.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Parent shall, or shall cause the Surviving Corporation to, honor the terms of all Benefit
Plans set forth in <U>Section&nbsp;6.5(b)</U> of the Company Disclosure
Schedule. Notwithstanding the foregoing, no provision of this Agreement shall (i)&nbsp;create any
right in any Employee to continued employment by Parent, the Company, the Surviving Corporation or
any respective subsidiary thereof, or preclude the ability of Parent, the Company, the Surviving
Corporation or any respective subsidiary thereof, to terminate the employment of any employee for
any reason or (ii)&nbsp;require Parent, the Company, the Surviving Corporation, or any respective
subsidiary thereof, to continue any Benefit Plan or prevent the amendment, modification, or
termination thereof after the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Parent agrees that the Company shall be permitted to pay (in accordance with <U>Section
6.5(c)</U> of the Company Disclosure Schedule), immediately prior to the Effective Time (to the
extent not theretofore paid), 2008 incentive compensation to Employees who participate in the
Company&#146;s annual incentive plans for fiscal year 2008. Such payments shall be made in accordance
with the Company&#146;s annual incentive plans for fiscal year 2008 and all determinations relating
thereto shall be consistent with the incentive compensation paid to Employees for fiscal year 2007.
<U>Section&nbsp;6.5(c)</U> of the Company Disclosure Schedule sets forth the actual bonuses to be paid
to Employees under the Company&#146;s annual incentive plans for fiscal year 2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;This <U>Section&nbsp;6.5</U> shall be binding upon and shall inure solely to the benefit of
each of the parties to this Agreement, and nothing in this <U>Section&nbsp;6.5</U>, express or implied,
is intended to confer upon any other Person any rights or remedies of any nature whatsoever under
or by reason of this <U>Section&nbsp;6.5</U> or is intended to be, shall constitute or be construed as
an amendment to or modification of any employee benefit plan, program, arrangement or policy of
Parent, the Company, the Surviving Corporation or any respective subsidiary thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.6 <U>Publicity</U>. The initial press release by each of Parent and the Company with respect to the execution of
this Agreement shall be reasonably acceptable to Parent and the Company. Neither the Company nor
Parent (nor any of their respective Affiliates) shall issue any other press release or make any
other public announcement with respect to this Agreement or the transactions contemplated hereby
without the prior agreement of the other party, except as may be required by Law or by any listing
agreement with a national securities exchange, in which case the party proposing to issue such
press release or make such public announcement shall use its reasonable efforts to consult in good
faith with the other party before making any such public announcements; <U>provided</U> that the
Company will no longer be required to obtain the prior agreement of or consult with Parent in
connection with any such press release or public announcement if the Company&#146;s Board of Directors
has effected any Change in Recommendation or shall have resolved to do so.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.7 <U>Directors&#146; and Officers&#146; Insurance and Indemnification</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;From and after the Effective Time, Parent and the Surviving Corporation shall, and Parent
shall cause the Surviving Corporation to, assume the obligations with respect to all rights to
indemnification, advancement of expenses and exculpation from liabilities for acts or omissions
occurring at or prior to the Effective Time now existing in favor of the current or former
directors or officers of the Company or any of its Subsidiaries (&#147;<U>Indemnified Parties</U>&#148;) as
provided in the Company&#146;s certificate of incorporation, bylaws or any indemnification agreement
between an Indemnified Party and the Company or any of its Subsidiaries (in each case, as in effect
on the date hereof or as amended or entered into prior to the Closing with the consent of Parent),
without further action, as of the Effective Time and such obligations shall survive the Merger and
shall continue in full force and effect in accordance with their terms. The certificate of
incorporation and bylaws of the Surviving Corporation shall contain the provisions with respect to
indemnification, advancement of expenses and limitation of director liability set forth in the
certificate of incorporation and bylaws of the Company on the date of this Agreement, which
provisions thereafter shall not be amended, repealed or otherwise modified in any manner that would
adversely affect the rights thereunder of the Indemnified Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Parent shall obtain, at the Effective Time, a prepaid (or &#147;tail&#148;) directors&#146; and officers&#146;
liability insurance policy in respect of acts or omissions occurring at or prior to the Effective
Time for six (6)&nbsp;years from the Effective Time, covering each person currently covered by the
Company&#146;s directors&#146; and officers&#146; liability insurance policy (a complete and accurate copy of
which has been heretofore made available to Parent) (collectively, the &#147;<U>Insured Parties</U>&#148;)
on terms with respect to such coverage and amounts no less favorable than those of such policy in
effect on the date of this Agreement; <U>provided</U>, <U>however</U>, that in satisfying its
obligations under this <U>Section&nbsp;6.7(b)</U>, Parent shall not be obligated to pay more than
$1,040,000 in the aggregate to obtain such policy. It is understood and agreed that in the event
such a policy cannot be obtained for $1,040,000 or less in the aggregate, Parent shall be obligated
to obtain as much coverage
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">for not less than six (6)&nbsp;years from the Effective Time as may be
obtained for such $1,040,000 aggregate amount.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Parent shall pay all reasonable expenses, including reasonable attorneys&#146; fees, that may
be incurred by any Indemnified Party in enforcing the indemnity and other obligations provided in
this <U>Section&nbsp;6.7</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;This <U>Section&nbsp;6.7</U> is intended to benefit the Insured Parties and the Indemnified
Parties and their successors, heirs or representatives, and shall be binding on all successors and
assigns of Parent, Sub, the Company and the Surviving Corporation. Parent hereby guarantees the
payment and performance by the Surviving Corporation of the indemnification and other obligations
pursuant to this <U>Section&nbsp;6.7</U> and the certificate of incorporation and bylaws of the
Surviving Corporation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;In the event that Parent, the Surviving Corporation or any of their successors or assigns
(i)&nbsp;consolidates with or merges into any other Person and shall not be the continuing or surviving
Person of such consolidation or merger or (ii)&nbsp;transfers or conveys a majority of its properties
and assets to any Person, then, and in each such case, proper provision shall be made so that the
successors, assigns and transferees of Parent or the Surviving Corporation or their respective
successors or assigns, as the case may be, assume the obligations set forth in this <U>Section
6.7</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.8 <U>Company Special Meeting; Proxy Statement</U>. If required by applicable Law to consummate the Merger, the Company shall, in accordance with
applicable Law and its certificate of incorporation and bylaws, duly call, give notice of, convene
and hold a special meeting of the Company&#146;s stockholders (including any adjournment or postponement
thereof, the &#147;Company Special Meeting&#148;) as soon as practicable following Sub&#146;s acceptance of and
payment for Shares pursuant to the Offer, for the purpose of considering adopting this Agreement.
In connection with the Company Special Meeting, as soon as practicable following Sub&#146;s acceptance
of and payment for Shares pursuant to the Offer, the Company shall prepare with Parent and file
with the SEC a proxy statement (together with all amendments and supplements thereto, the &#147;Proxy
Statement&#148;) relating to the Merger and this Agreement and furnish the information required to be
provided to the stockholders of the Company pursuant to the DGCL and any other applicable Laws.
Parent and Sub, on the one hand, and the Company, on the other hand, agree to promptly correct any
information provided by it for use in the Proxy Statement if it shall have become false or
misleading in any material respect or as otherwise required by applicable Law. The Company further
agrees to take all steps necessary to cause the Proxy Statement as so amended or supplemented to be
filed with the SEC and disseminated to holders of Shares to the extent required by applicable Laws.
The Company agrees to provide Parent and its counsel any comments or communications, whether
written or oral, that the Company or its counsel may receive from time to time from the SEC or its
staff with respect to the Proxy Statement promptly after receipt of such comments or
communications. Parent and its counsel shall be given
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">a reasonable opportunity to review any
responses to such comments or communications, and the Company shall give due consideration to all
reasonable additions, deletions or changes suggested thereto by Parent and its counsel.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.9 <U>Reasonable Efforts</U>. Upon the terms and subject to the conditions set forth in this Agreement, the Company and Parent
shall (and the Company shall cause its Subsidiaries to) each use their reasonable efforts to
promptly (i)&nbsp;take, or to cause to be taken, all actions, and to do, or to cause to be done, and to
assist and cooperate with the other parties in doing all things necessary, proper or advisable
under applicable Law or otherwise to consummate and make effective the transactions contemplated by
this Agreement; (ii)&nbsp;obtain from any Governmental Entities any actions, non-actions, clearances,
waivers, consents, approvals, permits or orders required to be obtained by the Company or Parent or
any of its Subsidiaries in connection with the authorization, execution, delivery and performance
of this Agreement and the consummation of the transactions contemplated hereby; (iii)
make all registrations, filings, notifications or submissions which are necessary or advisable, and
thereafter make any other required submissions, with respect to this Agreement, the Offer and the
Merger required under (A)&nbsp;any applicable federal or state securities Laws, (B)&nbsp;the Israeli
Anti-Trust Law and any other applicable antitrust laws, (C)&nbsp;the Law for the Encouragement of
Capital Investment, 5719-1959, and the regulations and approvals promulgated thereunder, (D)&nbsp;the
Encouragement of Industrial Research and Development Law, 5744-1984, and the regulations and grant
approvals promulgated thereunder by the OCS and (E)&nbsp;any other applicable Law; <U>provided</U>,
<U>however</U>, that the Company and Parent will cooperate with each other in connection with the
making of all such filings, including providing copies of all such filings and attachments to
outside counsel for the non-filing party and including the timing of the initial filings, which
will be made as promptly as practicable after the date of this Agreement; (iv)&nbsp;furnish all
information required for any application or other filing to be made pursuant to any applicable Law
in connection with the transactions contemplated by this Agreement; (v)&nbsp;keep the other party
informed in all material respects of any material communication received by such party from, or
given by such party to, any Governmental Entity and of any material communication received or given
in connection with any proceeding by a private party, in each case relating to the transactions
contemplated by this Agreement; (vi)&nbsp;permit the other parties to review any material written
communication delivered to any Governmental Entity relating to the transactions contemplated by
this Agreement or in connection with any proceeding by a private party relating thereto; (vii)
obtain all necessary consents, approvals or waivers from third parties; provided that none of the
Company, Parent or Sub shall be required to make any payment to any such third parties or concede
anything of value to obtain such consents; (viii)&nbsp;avoid the entry of, or have vacated or
terminated, any decree, order, or judgment that would restrain, prevent or delay the consummation
of the transactions contemplated hereby, including defending any lawsuits or other legal
proceedings, whether judicial or administrative, challenging this Agreement or the consummation of
the transactions contemplated hereby; and (ix)&nbsp;execute and deliver any additional instruments
necessary to consummate the transactions contemplated by this Agreement. Nothing in this Agreement
shall be deemed to require Parent to agree to, or proffer to, divest or hold separate any assets or
any portion of any business of Parent, the Company or any of their respective Subsidiaries. No
parties to
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">this Agreement shall consent to any voluntary delay of the consummation of the
transactions contemplated hereby at the behest of any Governmental Entity without the consent of
the other parties to this Agreement, which consent shall not be unreasonably withheld. The Company
and its Board of Directors shall (1)&nbsp;use their reasonable efforts to ensure that no state takeover
statute or similar statute or regulation is or becomes applicable to this Agreement, the Offer, the
Merger or any of the other transactions contemplated by this Agreement and (2)&nbsp;if any state
takeover statute or similar statute becomes applicable to this Agreement, the Offer, the Merger or
any of the other transactions contemplated by this Agreement, use their reasonable efforts to
ensure that the Offer, the Merger and the other transactions contemplated by this Agreement may be
consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to
minimize the effect of such statute or regulation on this Agreement, the Offer, the Merger and the
other transactions contemplated by this Agreement. Parent consents to the delivery by the Company
to the
OCS of Parent&#146;s executed undertaking in the form attached as <U>Exhibit&nbsp;C</U> to this Agreement if
required by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.10 <U>Sub and Surviving Corporation</U>. Parent will take all actions necessary to (a)&nbsp;cause Sub and the Surviving Corporation to perform
promptly their respective obligations under this Agreement, (b)&nbsp;cause Sub to consummate the Offer
and the Merger on the terms and conditions set forth in this Agreement and (c)&nbsp;ensure that, prior
to the Effective Time, Sub shall not conduct any business, make any investments or incur or
guarantee any indebtedness, other than acquiring Shares pursuant to the Offer.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.11 <U>No Control of Other Party&#146;s Business</U>. Nothing contained in this Agreement is intended to give Parent or Sub, directly or indirectly,
the right to control or direct the Company&#146;s or its Subsidiaries&#146; operations prior to the Effective
Time. Prior to the Effective Time, the Company shall exercise, consistent with the terms and
conditions of this Agreement, complete control and supervision over its and its Subsidiaries&#146;
respective operations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.12 <U>Israeli Tax Ruling</U>. The Company may instruct its Israeli counsel, advisors and accountants to prepare and file with
the Israeli Income Tax Commissioner an application for a ruling that confirms that the payment of
the consideration pursuant to this Agreement in exchange for Restricted Stock Awards, Company RSUs
and/or Company Options held in trust at the Effective Time under the Israeli Equity Plan will not
result in an immediate taxable event for the Person entitled to such Restricted Stock Awards,
Company RSUs and/or Company Options if such consideration is paid directly to the Trustee and until
such time as such consideration is subsequently paid by the Trustee to the Person entitled thereto,
whether at the end of the statutory holding period or otherwise, in accordance with the terms of
such ruling (which ruling may be subject to customary conditions regularly associated with such a
ruling) (the &#147;<U>Israeli Tax Ruling</U>&#148;). Each of the Company and the Parent shall cause their
respective Israeli counsel, advisors and accountants to coordinate all activities and to cooperate
with each other, with respect to the Company&#146;s preparation and filing of such application and in
the preparation of any written or oral submissions that may be necessary, proper or advisable to
obtain the Israeli Tax Ruling.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.13 <U>Certain Tax Matters</U>. (i)&nbsp;During the period from the date of this Agreement to the Closing Date, the Company and its
Subsidiaries shall: (a)&nbsp;prepare and timely file all Tax Returns that are due on or before the
Closing Date in accordance with past practice, (b)&nbsp;pay all Taxes due and payable in respect of such
Tax Returns, (c)&nbsp;accrue a reserve in the books and financial statements of any such entity at such
times and in such amounts as are in accordance with past practice for all Taxes payable by such
entity for which no Tax Return is due prior to the Closing Date and (d)&nbsp;promptly notify Parent of
any suit, claim, action, investigation,
proceeding, or audit (collectively, &#147;Actions&#148;) that is or becomes pending against or with respect
to the Company or any of its Subsidiaries and not settle or compromise any such Action without
Parent&#146;s consent (which will not be unreasonably withheld).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;The Company shall deliver to Parent at or prior to the Closing a properly executed
statement in the form attached as <U>Exhibit&nbsp;D</U> to this Agreement for purposes of satisfying
the requirements of Treasury Regulation&nbsp;Section&nbsp;1.1445-2(c)(3).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.14 <U>Stockholder Litigation</U>. The Company shall give Parent the opportunity to participate in the defense or settlement of any
stockholder litigation against the Company and/or its directors relating to the transactions
contemplated by this Agreement, and no such settlement shall be agreed to without Parent&#146;s prior
written consent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.15 <U>Rule&nbsp;14(d)-10(d) Matters</U>. Prior to the Initial Expiration Time, if applicable, the Company (acting through its Board of
Directors and the Compensation Committee thereof) shall take all such steps as may be required to
cause to be exempt under Rule&nbsp;14(d)-10(d) promulgated under the Exchange Act any employment
compensation, severance or other employee benefit arrangement that has been or will be entered into
by the Company, Parent or any of their respective Affiliates with current or future directors,
officers or employees of the Company and its Affiliates and to ensure that any such arrangements
fall within the safe harbor provisions of such Rule. Promptly upon Parent or any of its Affiliates
entering into any such arrangement with any current or future director, officer or employee of the
Company and its Affiliates, Parent will provide to the Company any and all information concerning
such arrangements as may be needed by the Company to comply with this <U>Section&nbsp;6.15</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.16 <U>Certain Other Actions</U>. The Company shall, using the applicable degree of efforts specified in <U>Section&nbsp;6.16</U> of
the Company Disclosure Schedule, take, or cause to be taken, all actions and do, or cause to be
done, all things necessary, proper or advisable to accomplish the items set forth in <U>Section
6.16</U> of the Company Disclosure Schedule as promptly as practicable after the date hereof (and
in any event prior to the Acceptance Date).
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>CONDITIONS</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.1 <U>Conditions to Each Party&#146;s Obligation to Effect the Merger</U>. The obligations of the Company, on the one hand, and Parent and Sub, on the other hand, to
consummate the Merger are subject to the satisfaction (or waiver by the
Company, Parent and Sub, if permissible under applicable Law) of the following conditions:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;The Company Stockholder Approval shall have been obtained, if and to the extent required
under applicable Law; <U>provided</U> that Parent and Sub shall, and shall cause any other Parent
Company to, vote all Shares held by them in favor of the adoption of this Agreement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;no Governmental Entity having jurisdiction over the Company, Parent or Sub shall have
issued a final, non-appealable order, decree or ruling or taken any other action which is then in
effect which has the effect of enjoining or otherwise prohibiting consummation of the Merger
substantially on the terms contemplated by this Agreement; <U>provided</U>, <U>however</U>, that
the parties hereto shall have used reasonable efforts to cause any such order, decree, ruling or
action to be vacated or lifted or to ameliorate the effects thereof; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Sub shall have accepted for payment all Shares validly tendered and not withdrawn pursuant
to the Offer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.2 <U>Frustration of Conditions</U>. None of the Company, Parent or Sub may rely on the failure of any condition set forth in
<U>Section&nbsp;7.1</U> or in <U>Annex A</U> to be satisfied if such failure was caused by such
party&#146;s failure to act in good faith or use its reasonable efforts to consummate the Offer and the
Merger and the other transactions contemplated by this Agreement, as required by and subject to
<U>Section&nbsp;6.9</U>.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>TERMINATION</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.1 <U>Termination</U>. Anything herein or elsewhere to the contrary notwithstanding, this Agreement may be terminated
and the Offer and the Merger contemplated herein may be abandoned as follows:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;at any time, by the mutual written agreement of the Company and Parent;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;by either the Company or Parent:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) if the Offer has not been consummated on or prior to May&nbsp;22, 2009 (the
&#147;<U>Termination Date</U>&#148;); <U>provided</U>, <U>however</U>, that the right to
terminate this Agreement under this <U>Section&nbsp;8.1(b)(i)</U> shall not be
available to any party whose failure to fulfill any obligation under this
Agreement has been a cause of, or resulted in, the failure of the Offer to be
consummated on or prior to such date;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) prior to the Acceptance Time, if any Governmental Entity having
jurisdiction over the Company, Parent or Sub shall have issued an order, decree or
ruling or taken any other action, in each case permanently enjoining or otherwise
prohibiting the consummation of the Offer or the Merger substantially as
contemplated by this Agreement and such order, decree, ruling or other action
shall have become final and non-appealable; <U>provided</U>, <U>however</U>, the
party seeking to terminate this Agreement under this <U>Section&nbsp;8.1(b)(ii)</U>
shall have used reasonable efforts to cause any such order, decree, ruling or
action to be vacated or lifted or to ameliorate the effects thereof; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) (A)&nbsp;if the Offer shall have expired or terminated in accordance with
its terms without any Shares being purchased therein or (B)&nbsp;if Sub shall have
failed to commence the Offer by the date that is the fifth (5th) Business Day from
and including the date of this Agreement; <U>provided</U>, <U>however</U>, that
the right to terminate this Agreement under this <U>Section&nbsp;8.1(b)(iii)</U> shall
not be available to the Company or Parent if its failure to fulfill any obligation
under this Agreement has been the cause of, or resulted in, the failure of any
Shares to be purchased in the Offer or the failure to commence the Offer by such
date, as the case may be;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;by the Company prior to the Acceptance Time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) upon a material breach of any representation, warranty, covenant or
agreement on the part of Parent or Sub set forth in this Agreement, or if any
representation or warranty of Parent or Sub shall have become untrue in any
material respect; <U>provided</U> that if such breach is curable by Parent and
Sub within thirty (30)&nbsp;days through the exercise of their reasonable efforts
during such thirty (30)&nbsp;day period and Parent and Sub continue to exercise such
reasonable efforts, the Company may not terminate this Agreement under this
<U>Section&nbsp;8.1(c)(i)</U> unless such breach is not cured within such thirty (30)
day period; <U>provided</U> <U>further</U> that the right to terminate this
Agreement under this <U>Section&nbsp;8.1(c)(i)</U> shall not be
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">available to the
Company if it has failed to perform in any material respect any of its obligations
under or in connection with this Agreement; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) in accordance with the terms and subject to the conditions of
<U>Section&nbsp;6.4(c)</U>; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;by Parent prior to the Acceptance Time:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) upon a breach of any representation, warranty, covenant or agreement on
the part of the Company set forth in this Agreement, or if any representation or
warranty of the Company shall have become untrue, in any case such that the
conditions set forth in clauses (v)(b) or (v)(c) of <U>Annex A</U> would not be
satisfied; <U>provided</U> that if such breach is curable by the Company within
thirty (30)&nbsp;days through the exercise of its reasonable efforts during such thirty
(30)&nbsp;day period and the Company continues to exercise such reasonable efforts,
Parent may not terminate this Agreement under this <U>Section&nbsp;8.1(d)(i)</U>
unless such breach is not cured within such thirty (30)&nbsp;day period;
<U>provided</U> <U>further</U> that the right to terminate this Agreement under
this <U>Section&nbsp;8.1(d)(i)</U> shall not be available to Parent if it or Sub has
failed to perform in any material respect any of their obligations under or in
connection with this Agreement; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) in the event that the Board of Directors of the Company (A)&nbsp;shall have
effected a Change in Recommendation or (B)&nbsp;fails publicly to reaffirm its
recommendation of this Agreement and the transactions contemplated hereby (x)
within ten (10)&nbsp;Business Days of receipt of a written request by Parent to provide
such reaffirmation following an Acquisition Proposal or (y)&nbsp;if the Termination
Date is less than ten (10)&nbsp;Business Days (but more than four (4)&nbsp;Business Days)
from the receipt of such a request by Parent following an Acquisition Proposal, by
the close of business on the Business Day immediately preceding the Termination
Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.2 <U>Effect of Termination</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;In the event of the termination of this Agreement in accordance with <U>Section&nbsp;8.1</U>,
written notice thereof shall forthwith be given to the other party or parties specifying the
provision hereof pursuant to which such termination is made, and this Agreement shall forthwith
become null and void, and there shall be no liability on the part of Parent, Sub or the Company or
their respective directors, officers, employees, stockholders, Representatives, agents or advisors
other than, with respect to Parent, Sub and the Company, the obligations pursuant to this
<U>Section&nbsp;8.2</U>, <U>ARTICLE IX</U> and the last two sentences of <U>Section&nbsp;6.3</U> and
<U>provided</U> that, notwithstanding anything to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the contrary contained in this Agreement, the
Nondisclosure Agreement shall survive any such termination in accordance with its terms. Nothing
contained in this <U>Section&nbsp;8.2</U> shall
relieve any party from liability for fraud or any statement, act or failure to act that is
intended to be a misrepresentation or breach by such party of any representation, covenant or
agreement herein (including failure to consummate the Offer in accordance with its terms) or in the
Nondisclosure Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If (i)&nbsp;this Agreement is terminated by the Company pursuant to <U>Section&nbsp;8.1(c)(ii)</U>
or by Parent pursuant to <U>Section&nbsp;8.1(d)(ii)</U> or (ii)&nbsp;(A) this Agreement is terminated by
either Parent or the Company pursuant to <U>Section&nbsp;8.1(b)(i)</U> or <U>Section&nbsp;8.1(b)(iii)</U>,
(B)&nbsp;there has been publicly disclosed for the first time after the date of this Agreement and prior
to such termination an Acquisition Proposal (or the intention by any Person to make an Acquisition
Proposal) and (C)&nbsp;within twelve (12)&nbsp;months after such termination, the Company enters into a
definitive agreement with respect to (or consummates) a transaction contemplated by any Acquisition
Proposal, then, in either case, the Company shall pay to Parent a termination fee of $13,150,000.00
in cash, (x)&nbsp;concurrently with any termination of this Agreement (in the case of a payment required
by clause (i)&nbsp;above) or (y)&nbsp;on the date of the first to occur of the events referred to in clause
(ii)(C) (in the case of a payment required by clause (ii)&nbsp;above). For purposes of clause (ii)(C)
of the immediately preceding sentence, the term &#147;<U>Acquisition Proposal</U>&#148; shall have the
meaning assigned to such term in <U>Section&nbsp;1.1</U> except that the references to &#147;15%&#148; therein
shall be deemed to be references to &#147;40%&#148;. Notwithstanding the foregoing, in no event shall the
Company be required to pay the fee referred to in this <U>Section&nbsp;8.2(b)</U> (X)&nbsp;on more than one
occasion or (Y)&nbsp;if, at the time this Agreement is terminated, this Agreement could have been
terminated by the Company pursuant to <U>Section&nbsp;8.1(b)(ii)</U> or <U>Section&nbsp;8.1(c)(i)</U>.
Upon payment of such fee, the Company shall have no further liability to Parent or Sub with respect
to this Agreement or the transactions contemplated hereby. Notwithstanding anything else herein to
the contrary, the payment contemplated by this <U>Section&nbsp;8.2(b)</U> shall be made by wire
transfer of immediately-available funds to an account designated by Parent and shall be reduced by
any amounts required to be deducted or withheld therefrom under applicable Law in respect of Taxes.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U><B>MISCELLANEOUS</B></U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.1 <U>Amendment and Modification</U>. Subject to the applicable provisions of the DGCL, at any time prior to the Effective Time, the
parties hereto may modify or amend this Agreement, by written agreement executed and delivered by
duly authorized officers of the respective parties; <U>provided</U>, <U>however</U>, that after
approval of this Agreement by the stockholders of the Company, no amendment shall be made which
changes the consideration payable in the Merger or adversely affects the rights of the Company&#146;s
stockholders hereunder or is otherwise required under any applicable Law to be approved by such
stockholders without, in each case, the approval of such stockholders.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.2 <U>Nonsurvival of Representations and Warranties</U>. None of the representations and warranties of the Company in this Agreement or in any schedule,
instrument or other document delivered pursuant to this Agreement shall survive the acceptance for
payment of the Shares by Sub pursuant to the Offer. This <U>Section&nbsp;9.2</U> shall not limit any
covenant or agreement contained in this Agreement that by its terms is to be performed in whole or
in part after the Acceptance Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.3 <U>Notices</U>. All notices, consents and other communications hereunder shall be in writing and shall be given
(and shall be deemed to have been duly given upon receipt) by hand delivery, by prepaid overnight
courier (providing written proof of delivery), by confirmed facsimile transmission or by certified
or registered mail (return receipt requested and first-class postage prepaid), addressed as
follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">(a)&nbsp;if to Parent or Sub, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Johnson &#038; Johnson<BR>
One Johnson &#038; Johnson Plaza<BR>
New Brunswick, New Jersey 08933<BR>
Facsimile: (732)&nbsp;524-2788<BR>
Attention: Office of the General Counsel
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">with a copy to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Cravath, Swaine &#038; Moore LLP<BR>
825 Eighth Avenue<BR>
New York, New York 10019<BR>
Telephone: (212)&nbsp;474-1964<BR>
Facsimile: (212)&nbsp;474-1000<BR>
Attention: Robert I. Townsend III, Esq.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">if to the Company, to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Omrix Biopharmaceuticals, Inc.<BR>
1120 Avenue of the Americas, Fourth Floor<BR>
New York, New York 10036<BR>
Telephone: (212)&nbsp;887-6509<BR>
Facsimile: (212)&nbsp;887-6550<BR>
Attention: Nanci Prado, Esq.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">with a copy to:
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-left: 9%; margin-top: 6pt">Skadden, Arps, Slate, Meagher &#038; Flom LLP<BR>
Four Times Square<BR>
New York, New York 10036<BR>
Telephone: (212)&nbsp;735 3000<BR>
Facsimile: (212)&nbsp;735-2000<BR>
Attention: David Fox and Randall H. Doud
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or to such other address or facsimile number for a party as shall be specified in a notice given in
accordance with this section; <U>provided</U> that any notice received by facsimile transmission
or otherwise at the addressee&#146;s location on any Business Day after 5:00 P.M. (addressee&#146;s local
time) or on any day that is not a Business Day shall be deemed to have been received at 9:00 A.M.
(addressee&#146;s local time) on the next Business Day; <U>provided</U> <U>further</U> that notice of
any change to the address or any of the other details specified in or pursuant to this section
shall not be deemed to have been received until, and shall be deemed to have been received upon,
the later of the date specified in such notice or the date that is five (5)&nbsp;Business Days after
such notice would otherwise be deemed to have been received pursuant to this section. A party&#146;s
rejection or other refusal to accept notice hereunder or the inability of another party to deliver
notice to such party because of such party&#146;s changed address or facsimile number of which no notice
was given by such party shall be deemed to be receipt of the notice by such party as of the date of
such rejection, refusal or inability to deliver. Nothing in this section shall be deemed to
constitute consent to the manner or address for service of process in connection with any legal
proceeding, including litigation arising out of or in connection with this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.4 <U>Interpretation</U>. The parties have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be
construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.
Disclosure of any fact, circumstance or information in any section of the Company Disclosure
Schedule shall be deemed to be adequate response and disclosure of such fact, circumstance or
information with respect to any representation or warranty in any section of <U>ARTICLE IV</U>
calling for disclosure of such fact, circumstance or information if it is reasonably apparent from
the face of such disclosure that such disclosure relates to one or more or all of such
representations or warranties. The inclusion of any item in the Company Disclosure Schedule shall
not be deemed to be an admission or evidence of materiality of such item, nor shall it establish
any standard of materiality for any purpose whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.5 <U>Counterparts</U>. This Agreement may be executed in multiple counterparts, all of which shall together be
considered one and the same agreement. Delivery of an executed signature page to this Agreement by
electronic transmission shall be as effective as delivery of a manually signed counterpart of this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.6 <U>Entire Agreement; Third-Party Beneficiaries</U>. This Agreement (including the Company Disclosure Schedule and the exhibits hereto, together with
the other instruments referred to herein) and the Nondisclosure Agreement (a)&nbsp;constitute the entire
agreement and supersede all prior agreements and understandings,
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->69<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">both written and oral, among the
parties with respect to the subject matter hereof and (b)&nbsp;are not intended to confer upon any
Person other than the parties hereto any rights or remedies hereunder; <U>provided</U>,
<U>however</U>, that it is specifically intended that (A)&nbsp;the Insured Parties and the Indemnified
Parties (with respect to <U>Section&nbsp;6.7</U> from and after the Effective Time) and (B)&nbsp;the
Company&#146;s stockholders and holders of Company Options and Restricted Stock Awards (with respect to
their rights to receive any Merger Consideration or Option Consideration after the Effective Time)
are third-party beneficiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.7 <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of
competent jurisdiction or other authority to be invalid, void, unenforceable or against its
regulatory policy, the remainder of the terms, provisions, covenants and restrictions of this
Agreement shall remain in full force and effect and shall in no way be affected, impaired or
invalidated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.8 <U>Governing Law</U>. This Agreement shall be governed by, and construed in accordance with the laws of the State of
Delaware, without giving effect to any choice or conflict of laws provision or rule (whether of the
State of Delaware or any other jurisdiction) that would cause the application of the Laws of any
jurisdiction other than the State of Delaware.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.9 <U>Jurisdiction</U>. Each of the parties hereto hereby (a)&nbsp;expressly and irrevocably submits to the exclusive
personal jurisdiction of the Delaware Court of Chancery, any other court of the State of Delaware
and any Federal court sitting in the State of Delaware in the event any dispute arises out of this
Agreement or any of the transactions contemplated by this Agreement, (b)&nbsp;agrees that it will not
attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any
such court, (c)&nbsp;agrees that it will not bring any action relating to this Agreement or any of the
transactions contemplated by this Agreement in any court other than the Delaware Court of Chancery,
any other court of the State of Delaware and any Federal court sitting in the State of Delaware
and (d)&nbsp;each of the parties hereto agrees that each of the other parties shall have the right to
bring any action or proceeding for enforcement of a judgment entered by the Delaware Court of
Chancery, any other court of the State of Delaware and any Federal court sitting in the State of
Delaware. Each of Parent, Sub and the Company agrees that a final judgment in any action or
proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment
or in any other manner provided by Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.10 <U>Service of Process</U>. Each party irrevocably consents to the service of process outside the territorial jurisdiction
of the courts referred to in <U>Section&nbsp;9.9</U> hereof in any such action or proceeding by mailing
copies thereof by registered or certified United States mail, postage prepaid, return receipt
requested, to its address as specified in or pursuant to <U>Section&nbsp;9.3</U> hereof. However, the
foregoing shall not limit the right of a party to effect service of process on the other party by
any other legally available method.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->70<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.11 <U>Specific Performance</U>. Each of the parties hereto acknowledges and agrees that, in the event of any breach of this
Agreement, each nonbreaching party would be irreparably and immediately harmed and could not be
made whole by monetary damages. It is accordingly agreed that the parties hereto (a)&nbsp;will waive,
in any action for specific performance, the defense of adequacy of a remedy at law and (b)&nbsp;shall be
entitled, in addition to any other remedy to which they may be entitled at law or in equity, to
compel specific performance of this Agreement in any action instituted in accordance with
<U>Section&nbsp;9.9</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.12 <U>Assignment</U>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be
assigned by any of the parties hereto (whether by operation of law or otherwise) without the prior
written consent of the other parties, except that Parent or Sub, upon prior written notice to the
Company, may assign, in its sole discretion, any of or all its rights, interests and obligations
under this Agreement (a)&nbsp;in the case of Parent, to any direct or indirect wholly owned Subsidiary
of Parent and (b)&nbsp;in the case of Sub, to Parent or to any direct or indirect wholly owned
Subsidiary of Parent, but no such assignment shall relieve Parent or Sub, as applicable, of any of
its obligations hereunder. Subject to the preceding sentence, this Agreement will be binding upon,
inure to the benefit of and be enforceable by the parties and their respective permitted successors
and assigns.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.13 <U>Expenses</U>. All costs and expenses incurred in connection with the transactions contemplated hereby, this
Agreement and the consummation of the transactions contemplated hereby shall be paid by the party
incurring such costs and expenses, whether or not the transactions contemplated hereby are
consummated. Other than Taxes imposed upon a holder of Shares or Company Options, the Company
shall pay all Taxes incident to preparing for, entering into and carrying out this Agreement
(including (i)&nbsp;transfer, stamp and documentary Taxes or fees and (ii)&nbsp;sales, use, gains, real
property transfer and other or similar Taxes or fees), <U>provided</U>, <U>however</U>, that
Parent shall pay any real property transfer Taxes imposed on the holders of Shares which result
from the transactions contemplated herein. For the avoidance of doubt, neither Parent, Sub, nor
the Company shall be responsible for the payment of income Taxes imposed upon a holder of Shares
which result from the transactions contemplated herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.14 <U>Headings</U>. Headings of the articles and sections of this Agreement and the table of contents, schedules and
exhibits are for convenience of the parties only and shall be given no substantive or
interpretative effect whatsoever.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.15 <U>Waivers</U>. Except as otherwise provided in this Agreement, any failure of any of the parties to comply with
any obligation, covenant, agreement or condition herein may be waived by the party or parties
entitled to the benefits thereof only by a written instrument signed by the party expressly
granting such waiver, but such waiver or failure to insist upon strict compliance with such
obligation, covenant, agreement or condition shall not operate as a waiver of, or estoppel with
respect to, any subsequent or other failure.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->71<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt">&#091;<I>Signature page follows.</I>&#093;
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->72<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Company, Parent and Sub have caused this Agreement to be signed by
their respective officers thereunto duly authorized as of the date first written above.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">OMRIX BIOPHARMACEUTICALS, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ R. Taub
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">R. Taub&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">C.E.O&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">JOHNSON &#038; JOHNSON<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ John A. Papa
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">John A. Papa&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">BINDER MERGER SUB, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ James J. Bergin
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">James J. Bergin&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->73<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>ANNEX A</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CONDITIONS TO THE OFFER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any other provisions of the Offer (such term, and all other capitalized terms
used herein, shall have the meanings ascribed to them in the Agreement and Plan of Merger to which
this Annex A is attached) or the Agreement, Sub shall not be required to accept for payment,
purchase or pay for any Shares tendered pursuant to the Offer and, subject to any applicable rules
and regulations of the SEC, may postpone the acceptance for payment of, and the purchase and
payment for, any Shares tendered pursuant to the Offer if (i)&nbsp;there shall have been validly
tendered and not withdrawn prior to the expiration of the Offer (as it may be extended in
accordance with <U>Section&nbsp;2.1</U> of the Agreement) a number of Shares which, together with any
other Shares beneficially owned by the Parent Companies, constitute less than a majority of the
Shares outstanding on a fully-diluted basis on the date of purchase, (ii)&nbsp;the approval under the
Israeli Anti-Trust Law for the purchase of Shares pursuant to the Offer and for the consummation of
the Merger has not been received and the applicable waiting period (including any extension
thereof, by Law, the consent of the parties or otherwise) shall not have expired or terminated
prior to the expiration of the Offer (as it may be extended in accordance with <U>Section&nbsp;2.1</U>
of the Agreement), (iii)&nbsp;the approval of the Investment Center under the Law for the Encouragement
of Capital Investment for the purchase of Shares pursuant to the Offer and for the consummation of
the Merger has not been received, (iv)&nbsp;if required by applicable Law, the approval of the OCS for
the purchase of Shares pursuant to the Offer and for the consummation of the Merger has not been
received or (v)&nbsp;at any time on or after the date of the Agreement and prior to the acceptance for
payment of Shares pursuant to the Offer, any of the following events shall have occurred and be
continuing:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) (1)&nbsp;a Governmental Entity having jurisdiction over the Company, Parent or Sub shall have
issued an order, decree or ruling or taken any other action enjoining or otherwise prohibiting
consummation of the Offer or the Merger on the terms contemplated by the Agreement or (2)&nbsp;there
shall be pending or threatened any suit, proceeding, investigation or other action by any
Governmental Entity seeking to enjoin or otherwise prohibit consummation of the Offer or the Merger
on the terms contemplated by the Agreement; <U>provided</U>, <U>however</U>, that, in the case of
clause (1)&nbsp;and (2), Parent and Sub shall have used reasonable efforts to cause any such order,
decree, ruling, suit, proceeding, investigation or action to be vacated or lifted or to ameliorate
the effects thereof; <U>provided</U> <U>further</U> that, in the case of clause (1)&nbsp;and (2), if
any such order, decree, ruling, suit, proceeding, investigation or action is temporary or
preliminary in nature Parent and Sub may not, during the pendency thereof and by virtue of this
condition alone, amend or terminate the Offer (but Parent and Sub may only extend the Offer and
thereby postpone acceptance for payment and purchase of the Shares);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;any representation or warranty of the Company contained in the Agreement that is qualified
as to &#147;materiality&#148; or Company Material Adverse Effect shall not be true and correct (or any such
representation or warranty that is not so qualified shall not be true
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->1<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and correct in any material respect) in each case as of the date of the Agreement and as of
the Acceptance Date, other than any such representation or warranty that addresses matters only as
of a particular date or only with respect to a specific period of time which representations and
warranties need only be true and correct as of such date or with respect to such period;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;the Company shall not have performed in all material respects all its obligations under
the Agreement to be performed by it on or prior to the date of consummation of the Offer; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;the Agreement shall have been terminated in accordance with its terms.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing conditions shall be in addition to, and not in limitation of, the rights of
Parent and Sub to extend, terminate and/or modify the Offer as and to the extent permitted by the
Agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
